Enterolactone - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	Enterolactone	go back to main search page
Accession:	CHEBI:81555	browse the term
Definition:	A lignan that has formula C18H18O4.
Synonyms:	related_synonym:	2,3-Bis(3'-hydroxybenzyl)butyrolactone; 3,4-bis[(3-hydroxyphenyl)methyl]oxolan-2-one; Dihydro-3,4-bis((3-hydroxyphenyl)methyl)-2(3H)-Furanone; Formula=C18H18O4; InChI=1S/C18H18O4/c19-15-5-1-3-12(8-15)7-14-11-22-18(21)17(14)10-13-4-2-6-16(20)9-13/h1-6,8-9,14,17,19-20H,7,10-11H2/t14-,17+/m1/s1; InChIKey=HVDGDHBAMCBBLR-PBHICJAKSA-N; SMILES=Oc1cccc(C[C@@H]2COC(=O)[C@H]2Cc2cccc(O)c2)c1
	xref:	CAS:76543-15-2; CAS:78473-71-9; HMDB:HMDB0006101; KEGG:C18165; KNApSAcK:C00000703
	xref_mesh:	MESH:C029497
	xref:	MetaCyc:2-CHLORO-TRANS-DIENELACTONE; PMID:11216511; PMID:12107024; PMID:12270221; PMID:16168401; PMID:17976571

show annotations for term's descendants Sort by:
Rat (965) Mouse (965) Human (979) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (965)

Enterolactone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

RIKEN cDNA 6430548M08 gene like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIAA0513 mRNA

NCBI chr19:48,168,651...48,216,571
Ensembl chr19:48,198,209...48,216,575

G

aladin WD repeat nucleoporin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AAAS mRNA

NCBI chr 7:133,464,315...133,483,961
Ensembl chr 7:133,464,315...133,483,961

G

ATP binding cassette subfamily C member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily F member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABCF1 mRNA

NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433

G

ATP binding cassette subfamily G member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABCG1 mRNA

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

abhydrolase domain containing 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ABHD11 mRNA

NCBI chr12:21,682,206...21,685,331
Ensembl chr12:21,682,202...21,685,398

G

abhydrolase domain containing 12, lysophospholipase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ABHD12 mRNA

NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564

G

abhydrolase domain containing 2, acylglycerol lipase

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of ABHD2 mRNA

NCBI chr 1:133,217,403...133,298,564
Ensembl chr 1:133,217,375...133,299,061

G

acetyl-CoA acyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACAA2 mRNA

NCBI chr18:68,345,136...68,373,246
Ensembl chr18:68,345,012...68,373,249

G

acetyl-CoA acetyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

acyl-CoA binding domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACBD3 mRNA

NCBI chr13:92,455,813...92,484,556
Ensembl chr13:92,455,655...92,483,380

G

atypical chemokine receptor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:90,799,686...90,811,237

G

ATP citrate lyase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACLY mRNA

NCBI chr10:85,412,045...85,464,253
Ensembl chr10:85,412,049...85,463,320

G

acyl-CoA thioesterase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT4 mRNA

NCBI chr 6:103,668,699...103,674,037
Ensembl chr 6:103,668,753...103,673,917

G

acyl-CoA thioesterase 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACOT7 mRNA

NCBI chr 5:162,686,562...162,779,309
Ensembl chr 5:162,684,645...162,779,309

G

acylphosphatase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ACYP1 mRNA

NCBI chr 6:104,919,162...104,932,348
Ensembl chr 6:104,919,162...104,932,387

G

adenosine deaminase, tRNA-specific 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADAT1 mRNA

NCBI chr19:39,918,083...39,956,886
Ensembl chr19:39,918,227...39,956,883

G

adducin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ADD3 mRNA

NCBI chr 1:252,147,341...252,255,126
Ensembl chr 1:252,147,386...252,255,124

G

actin filament associated protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFAP1 mRNA

NCBI chr14:74,743,322...74,856,300
Ensembl chr14:74,743,320...74,856,263

G

ALF transcription elongation factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AFF4 mRNA

NCBI chr10:37,498,825...37,579,751
Ensembl chr10:37,498,825...37,579,751

G

anterior gradient 2, protein disulphide isomerase family member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR2 mRNA

NCBI chr 6:52,708,602...52,729,378
Ensembl chr 6:52,708,602...52,729,371

G

anterior gradient 3, protein disulphide isomerase family member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AGR3 mRNA

NCBI chr 6:52,643,391...52,666,638
Ensembl chr 6:52,643,391...52,666,638

G

ajuba LIM protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AJUBA mRNA

NCBI chr15:28,019,775...28,031,537
Ensembl chr15:28,019,778...28,030,021

G

A-kinase anchoring protein 13

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AKAP13 mRNA

NCBI chr 1:129,313,183...129,619,647
Ensembl chr 1:129,314,402...129,619,646

G

ALG6, alpha-1,3-glucosyltransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG6 mRNA

NCBI chr 5:114,404,972...114,454,440
Ensembl chr 5:114,405,010...114,454,439

G

ALG8, alpha-1,3-glucosyltransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ALG8 mRNA

NCBI chr 1:151,684,344...151,704,310
Ensembl chr 1:151,684,396...151,704,302

G

adenosylmethionine decarboxylase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMD1 mRNA

NCBI chr20:43,695,783...43,711,476
Ensembl chr20:43,697,237...43,711,476

G

AMMECR nuclear protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AMMECR1 mRNA

NCBI chr X:106,465,982...106,571,382
Ensembl chr X:106,466,699...106,571,487

G

angiomotin like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AMOTL2 mRNA

NCBI chr 8:103,303,368...103,319,161
Ensembl chr 8:103,302,992...103,318,910

G

anillin, actin binding protein

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANLN mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of ANLN mRNA

NCBI chr 8:20,858,227...20,921,602
Ensembl chr 8:20,858,228...20,921,538

G

anoctamin 6

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of ANO6 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANO6 mRNA

NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589

G

acidic nuclear phosphoprotein 32 family member E

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANP32E mRNA

NCBI chr 2:183,472,600...183,489,057
Ensembl chr 2:183,472,609...183,489,054

G

annexin A2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA2 mRNA

NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658

G

annexin A3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ANXA3 mRNA

NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617

G

annexin A9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ANXA9 mRNA

NCBI chr 2:182,873,185...182,884,501
Ensembl chr 2:182,872,929...182,883,374

G

adaptor related protein complex 1 subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1B1 mRNA

NCBI chr14:79,879,482...79,930,778
Ensembl chr14:79,879,533...79,930,778

G

adaptor related protein complex 1 subunit mu 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AP1M1 mRNA

NCBI chr16:17,586,886...17,602,410
Ensembl chr16:17,584,730...17,602,403

G

amyloid beta precursor protein binding family B member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of APBB2 mRNA

NCBI chr14:41,557,918...41,878,622
Ensembl chr14:41,557,972...41,877,495

G

aquaporin 3 (Gill blood group)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

ARFGEF family member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARFGEF3 mRNA

NCBI chr 1:13,245,578...13,404,319
Ensembl chr 1:13,244,830...13,404,084

G

Rho GDP dissociation inhibitor alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGDIA mRNA

NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023

G

Rho guanine nucleotide exchange factor 26

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARHGEF26 mRNA

NCBI chr 2:146,740,336...146,850,918
Ensembl chr 2:146,739,631...146,850,819

G

Rho guanine nucleotide exchange factor 37

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARHGEF37 mRNA

NCBI chr18:54,935,256...55,001,017
Ensembl chr18:54,949,110...55,000,669

G

ADP ribosylation factor like GTPase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ARL3 mRNA

NCBI chr 1:245,400,659...245,446,673
Ensembl chr 1:245,400,550...245,446,820

G

aristaless related homeobox

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ARX mRNA

NCBI chr X:58,016,233...58,028,149
Ensembl chr X:58,016,233...58,028,142

G

ArfGAP with SH3 domain, ankyrin repeat and PH domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ASAP1 mRNA

NCBI chr 7:95,786,130...96,093,111
Ensembl chr 7:95,787,818...96,092,754

G

anti-silencing function 1B histone chaperone

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASF1B mRNA

NCBI chr19:24,181,024...24,195,604
Ensembl chr19:24,181,028...24,195,549

G

assembly factor for spindle microtubules

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ASPM mRNA

NCBI chr13:51,074,849...51,123,755
Ensembl chr13:51,074,849...51,123,755

G

ATPase family, AAA domain containing 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATAD2 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of ATAD2 mRNA

NCBI chr 7:89,634,123...89,676,738
Ensembl chr 7:89,634,123...89,676,738

G

activating transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

atos homolog A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATOSA mRNA

NCBI chr 8:75,694,828...75,772,565
Ensembl chr 8:75,695,022...75,772,549

G

ATPase Na+/K+ transporting subunit beta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATP23 metallopeptidase and ATP synthase assembly factor homolog

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP23 mRNA

NCBI chr 7:62,714,752...62,729,893
Ensembl chr 7:62,714,785...62,729,862

G

ATPase plasma membrane Ca2+ transporting 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2B1 mRNA

NCBI chr 7:33,735,595...33,845,226
Ensembl chr 7:33,735,871...33,843,295

G

ATPase secretory pathway Ca2+ transporting 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP2C1 mRNA

NCBI chr 8:106,034,777...106,155,854
Ensembl chr 8:106,034,636...106,156,006

G

ATP synthase membrane subunit c locus 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATPase H+ transporting V0 subunit e1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP6V0E1 mRNA

NCBI chr10:16,479,656...16,502,732
Ensembl chr10:16,479,567...16,524,434

G

ATPase phospholipid transporting 9A (putative)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATP9A mRNA

NCBI chr 3:157,360,354...157,467,628
Ensembl chr 3:157,360,359...157,467,818

G

ATRX, chromatin remodeler

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of ATRX mRNA

NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330

G

ataxin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ATXN1 mRNA

NCBI chr17:18,737,491...19,142,360
Ensembl chr17:18,737,533...19,142,360

G

aurora kinase A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKA mRNA

NCBI chr 3:161,128,309...161,144,524
Ensembl chr 3:161,128,313...161,144,390

G

aurora kinase B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of B3GALNT1 mRNA

NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:153,846,474...153,877,332

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of B3GNT5 mRNA

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:81,140,599...81,156,166

G

beta-secretase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE1 mRNA

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

beta-secretase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BACE2 mRNA

NCBI chr11:36,707,447...36,789,550
Ensembl chr11:36,707,458...36,789,546

G

BAG cochaperone 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BAG3 mRNA

NCBI chr 1:183,103,038...183,126,862
Ensembl chr 1:183,102,871...183,126,858

G

BRCA1 associated RING domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BARD1 mRNA

NCBI chr 9:72,616,070...72,694,553
Ensembl chr 9:72,623,155...72,694,265

G

BCAR3 adaptor protein, NSP family member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCAR3 mRNA

NCBI chr 2:210,525,260...210,638,674
Ensembl chr 2:210,525,260...210,638,798

G

BCL2, apoptosis regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2 mRNA

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2 like 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BCL2L12 mRNA

NCBI chr 1:95,472,272...95,480,991
Ensembl chr 1:95,472,272...95,480,991

G

BCL3, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL3 mRNA

NCBI chr 1:79,471,368...79,485,908
Ensembl chr 1:79,471,369...79,485,607

G

BCL9, transcription coactivator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BCL9 mRNA

NCBI chr 2:184,760,616...184,846,261
Ensembl chr 2:184,760,618...184,786,435

G

brain expressed X-linked 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BEX2 mRNA

NCBI chr X:99,219,014...99,220,518
Ensembl chr X:99,219,014...99,220,958

G

basic helix-loop-helix family, member e40

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

baculoviral IAP repeat-containing 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BIRC5 mRNA

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BLM RecQ like helicase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLM mRNA

NCBI chr 1:134,409,832...134,496,073
Ensembl chr 1:134,409,857...134,484,312

G

B-cell linker

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BLNK mRNA

NCBI chr 1:239,753,640...239,821,113
Ensembl chr 1:239,753,648...239,821,113

G

bridge-like lipid transfer protein family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BLTP2 mRNA

NCBI chr10:63,155,999...63,185,213
Ensembl chr10:63,156,044...63,191,141

G

bMERB domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMERB1 mRNA

NCBI chr10:1,779,834...1,946,586
Ensembl chr10:1,779,835...1,946,575

G

Bcl2 modifying factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

bone morphogenetic protein 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMP7 mRNA

NCBI chr 3:161,639,915...161,716,938
Ensembl chr 3:161,516,462...161,716,788

G

bone morphogenetic protein receptor type 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BMPR2 mRNA

NCBI chr 9:61,192,718...61,307,280
Ensembl chr 9:61,190,566...61,301,809

G

BRCA1-associated ATM activator 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRAT1 mRNA

NCBI chr12:13,928,889...13,951,760
Ensembl chr12:13,928,898...13,941,248

G

BRCA1, DNA repair associated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA1 mRNA

NCBI chr10:86,417,441...86,477,762
Ensembl chr10:86,418,000...86,477,304

G

BRCA2, DNA repair associated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRCA2 mRNA

NCBI chr12:59,492...103,789
Ensembl chr12:59,819...100,567

G

Bri3 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BRI3BP mRNA

NCBI chr12:31,176,742...31,188,563
Ensembl chr12:31,173,971...31,188,572

G

bromodomain and WD repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BRWD1 mRNA

NCBI chr11:35,286,364...35,378,768
Ensembl chr11:35,288,313...35,378,768

G

BSD domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BSDC1 mRNA

NCBI chr 5:141,798,918...141,827,091
Ensembl chr 5:141,798,981...141,827,092

G

basigin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BSG mRNA

NCBI chr 7:9,993,170...10,000,387
Ensembl chr 7:9,993,170...10,000,387

G

BTG anti-proliferation factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of BTG1 mRNA

NCBI chr 7:31,341,391...31,343,649
Ensembl chr 7:31,341,027...31,343,649

G

BUB1 mitotic checkpoint serine/threonine kinase B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of BUB1B mRNA

NCBI chr 3:105,563,089...105,615,547
Ensembl chr 3:105,563,138...105,615,547

G

similar to human chromosome 9 open reading frame 40

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C9ORF40 mRNA

NCBI chr 1:216,128,687...216,132,896
Ensembl chr 1:216,128,651...216,133,045

G

similar to human chromosome 5 open reading frame 34

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5ORF34 mRNA

NCBI chr 2:51,553,223...51,577,090
Ensembl chr 2:51,555,432...51,577,085

G

complement C5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of C5 mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

similar to human chromosome 9 open reading frame 152

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of C9ORF152 mRNA

NCBI chr 5:72,660,573...72,667,941
Ensembl chr 5:72,660,573...72,668,379

G

cell adhesion molecule 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CADM1 mRNA

NCBI chr 8:47,847,836...48,178,703
Ensembl chr 8:47,847,325...48,182,833

G

calmodulin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALM3 mRNA

NCBI chr 1:77,590,668...77,597,776
Ensembl chr 1:77,589,230...77,592,207

G

calumenin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CALU mRNA

NCBI chr 4:57,949,086...57,976,589
Ensembl chr 4:57,948,997...57,976,593

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2D mRNA

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

calcium/calmodulin-dependent protein kinase II inhibitor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAMK2N1 mRNA

NCBI chr 5:150,674,819...150,676,600
Ensembl chr 5:150,673,507...150,676,600

G

carbonic anhydrase 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CA12 mRNA

NCBI chr 8:67,274,739...67,330,428
Ensembl chr 8:67,274,359...67,330,440

G

calcium regulated heat stable protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CARHSP1 mRNA

NCBI chr10:6,946,036...6,960,556
Ensembl chr10:6,946,959...7,020,019

G

calpastatin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CAST mRNA

NCBI chr 2:3,973,112...4,082,658
Ensembl chr 2:3,973,112...4,082,659

G

core-binding factor subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CBFB mRNA

NCBI chr19:33,049,162...33,092,752
Ensembl chr19:33,049,172...33,092,751

G

Cbl proto-oncogene B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CBLB mRNA

NCBI chr11:48,589,878...48,756,940
Ensembl chr11:48,592,703...48,756,839

G

coiled-coil domain containing 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC14 mRNA

NCBI chr11:66,052,063...66,087,915
Ensembl chr11:66,052,620...66,087,956

G

coiled-coil domain containing 34

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCDC34 mRNA

NCBI chr 3:96,553,074...96,588,310
Ensembl chr 3:96,552,992...96,588,146

G

cellular communication network factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cellular communication network factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCN5 mRNA

NCBI chr 3:152,491,247...152,502,639
Ensembl chr 3:152,491,220...152,502,636

G

cyclin B1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB1 mRNA

NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172

G

cyclin B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNB2 mRNA

NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874

G

cyclin E2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin F

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CCNF mRNA

NCBI chr10:13,253,073...13,279,140
Ensembl chr10:13,253,380...13,279,101

G

cell cycle progression 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CCPG1 mRNA

NCBI chr 8:73,719,960...73,752,437
Ensembl chr 8:73,719,955...73,752,430

G

CD55 molecule (Cromer blood group)

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of CD55 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD55 mRNA

NCBI chr13:41,857,242...41,885,966
Ensembl chr13:41,857,395...41,885,831

G

CD59b molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CD59 mRNA

NCBI chr 3:90,459,085...90,477,571
Ensembl chr 3:90,459,162...90,478,847

G

cell division cycle 25A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25A mRNA

NCBI chr 8:109,864,356...109,882,734
Ensembl chr 8:109,864,478...109,882,701

G

cell division cycle 25C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185

G

cell division cycle 27

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC27 mRNA

NCBI chr10:89,400,720...89,449,816
Ensembl chr10:89,400,940...89,449,736

G

cell division cycle 45

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC45 mRNA

NCBI chr11:82,185,427...82,210,630
Ensembl chr11:82,185,473...82,210,619

G

cell division cycle 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC6 mRNA

NCBI chr10:83,864,189...83,878,011
Ensembl chr10:83,864,638...83,878,011

G

cell division cycle 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDC7 mRNA

NCBI chr14:2,804,660...2,824,796
Ensembl chr14:2,804,661...2,824,778

G

cell division cycle associated 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA2 mRNA

NCBI chr15:41,895,946...41,942,226
Ensembl chr15:41,895,901...41,941,611

G

cell division cycle associated 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA3 mRNA

NCBI chr 4:157,634,775...157,638,799
Ensembl chr 4:157,634,928...157,638,799

G

cell division cycle associated 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA4 mRNA

NCBI chr 6:131,892,305...131,901,571
Ensembl chr 6:131,892,087...131,901,564

G

cell division cycle associated 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA5 mRNA

NCBI chr 1:203,378,550...203,392,027
Ensembl chr 1:203,378,577...203,392,023

G

cell division cycle associated 7 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA7L mRNA

NCBI chr 6:138,793,953...138,839,889
Ensembl chr 6:138,794,228...138,839,888

G

cell division cycle associated 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDCA8 mRNA

NCBI chr 5:137,176,414...137,198,686
Ensembl chr 5:137,176,417...137,198,629

G

cadherin 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDH12 mRNA

NCBI chr 2:70,474,679...71,705,369
Ensembl chr 2:70,475,043...71,700,572

G

cyclin-dependent kinase 1

increases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of CDK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK1 mRNA

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cyclin-dependent kinase 17

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCTK2 mRNA

NCBI chr 7:27,683,890...27,765,814
Ensembl chr 7:27,683,890...27,764,910

G

cyclin-dependent kinase 2 associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK2AP2 mRNA

NCBI chr 1:201,391,056...201,393,137
Ensembl chr 1:201,391,466...201,393,137

G

CDK5 regulatory subunit associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDK5RAP2 mRNA

NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN1A mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

cyclin-dependent kinase inhibitor 2C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN2C mRNA

NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278

G

cyclin-dependent kinase inhibitor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDKN3 mRNA

NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945

G

CDP-diacylglycerol synthase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CDS1 mRNA

NCBI chr14:7,820,328...7,882,943
Ensembl chr14:7,820,351...7,882,681

G

chromatin licensing and DNA replication factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CDT1 mRNA

NCBI chr19:50,620,713...50,625,659
Ensembl chr19:50,620,713...50,625,659

G

CCAAT/enhancer binding protein delta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

cadherin, EGF LAG seven-pass G-type receptor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CELSR2 mRNA

NCBI chr 2:196,029,206...196,053,848
Ensembl chr 2:196,029,434...196,053,845

G

centromere protein A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPA mRNA

NCBI chr 6:25,700,142...25,711,767
Ensembl chr 6:25,700,142...25,711,675

G

centromere protein F

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPF mRNA

NCBI chr13:101,184,127...101,229,714
Ensembl chr13:101,184,127...101,229,669

G

centromere protein H

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPH mRNA

NCBI chr 2:31,896,675...31,910,179
Ensembl chr 2:31,894,667...31,910,154

G

centromere protein I

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPI mRNA

NCBI chr X:97,515,919...97,567,671
Ensembl chr X:97,515,972...97,567,657

G

centromere protein L

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPL mRNA

NCBI chr13:73,337,235...73,352,115
Ensembl chr13:73,337,257...73,352,114

G

centromere protein N

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPN mRNA

NCBI chr19:44,971,265...44,994,019
Ensembl chr19:44,968,308...44,994,012

G

centromere protein O

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPO mRNA

NCBI chr 6:27,203,642...27,218,394
Ensembl chr 6:27,188,537...27,218,314

G

centromere protein Q

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPQ mRNA

NCBI chr 9:19,957,122...19,972,807
Ensembl chr 9:19,957,048...19,972,789

G

centromere protein S

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPS mRNA

NCBI chr 5:159,563,917...159,573,534

G

centromere protein U

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPU mRNA

NCBI chr16:45,715,821...45,739,038
Ensembl chr16:45,714,294...45,738,823

G

centromere protein W

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CENPW mRNA

NCBI chr 1:27,525,324...27,530,464
Ensembl chr 1:27,525,324...27,530,464

G

centrosomal protein 55

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP55 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of CEP55 mRNA

NCBI chr 1:235,832,823...235,848,401
Ensembl chr 1:235,832,878...235,848,394

G

centrosomal protein 57

increases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of CEP57 mRNA

NCBI chr 8:10,669,588...10,689,257
Ensembl chr 8:10,669,590...10,689,249

G

centrosomal protein 78

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP78 mRNA

NCBI chr 1:213,246,183...213,275,275
Ensembl chr 1:213,246,187...213,275,181

G

centrosomal protein 85

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CEP85 mRNA

NCBI chr 5:146,356,571...146,404,155
Ensembl chr 5:146,356,576...146,404,060

G

ChaC glutathione specific gamma-glutamylcyclotransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAC2 mRNA

NCBI chr14:104,720,754...104,728,305
Ensembl chr14:104,720,758...104,728,301

G

chromatin assembly factor 1 subunit A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1A mRNA

NCBI chr 9:873,953...900,701
Ensembl chr 9:874,051...900,654

G

chromatin assembly factor 1 subunit B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHAF1B mRNA

NCBI chr11:33,200,894...33,221,076
Ensembl chr11:33,200,981...33,221,070

G

chromodomain helicase DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CHD2 mRNA

NCBI chr 1:127,188,146...127,317,041
Ensembl chr 1:127,190,059...127,300,502

G

checkpoint kinase 1

increases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of CHEK1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK1 mRNA

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

choline phosphotransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CHPT1 mRNA

NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103

G

Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CITED2 mRNA

NCBI chr 1:12,312,426...12,314,869
Ensembl chr 1:12,312,160...12,314,897

G

cytoskeleton associated protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKAP5 mRNA

NCBI chr 3:77,491,195...77,593,300
Ensembl chr 3:77,491,276...77,593,264

G

chemokine-like factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKLF mRNA

NCBI chr19:698,097...706,570
Ensembl chr19:698,033...706,570

G

CDC28 protein kinase regulatory subunit 1B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS1B mRNA

NCBI chr 2:174,833,025...174,837,614
Ensembl chr 2:174,833,050...174,837,636

G

CDC28 protein kinase regulatory subunit 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CKS2 mRNA

NCBI chr17:13,570,611...13,575,770

G

claudin 1

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of CLDN1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN1 mRNA

NCBI chr11:74,421,569...74,436,728
Ensembl chr11:74,421,569...74,436,724

G

claudin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLDN4 mRNA

NCBI chr12:21,751,638...21,753,436
Ensembl chr12:21,751,331...21,753,436

G

CAP-GLY domain containing linker protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLIP1 mRNA

NCBI chr12:32,910,932...33,017,891
Ensembl chr12:32,910,977...33,017,884

G

CLN6, transmembrane ER protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CLN6 mRNA

NCBI chr 8:63,303,356...63,318,360
Ensembl chr 8:63,303,029...63,318,360

G

clusterin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CLU mRNA

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

C-x(9)-C motif containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CMC2 mRNA

NCBI chr19:44,943,283...44,971,930
Ensembl chr19:44,943,285...44,971,983

G

collagen type V alpha 1 chain

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of COL5A1 mRNA

NCBI chr 3:11,208,429...11,356,715
Ensembl chr 3:11,208,512...11,354,588

G

capping protein inhibiting regulator of actin dynamics

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRACD mRNA

NCBI chr14:31,284,066...31,520,103
Ensembl chr14:31,284,184...31,522,431

G

cryptochrome circadian regulator 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CRY1 mRNA

NCBI chr 7:18,529,823...18,594,092
Ensembl chr 7:18,529,823...18,594,091

G

chromosome segregation 1 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSE1L mRNA

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

chondroitin sulfate proteoglycan 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CSPG5 mRNA

NCBI chr 8:110,220,506...110,234,766
Ensembl chr 8:110,220,653...110,234,758

G

cysteine and serine rich nuclear protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of AXUD1 mRNA

NCBI chr 8:119,704,712...119,717,767
Ensembl chr 8:119,704,713...119,718,183

G

cysteine and serine rich nuclear protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CSRNP2 mRNA

NCBI chr 7:131,594,232...131,610,075
Ensembl chr 7:131,594,232...131,610,075

G

CTD small phosphatase like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTDSPL2 mRNA

NCBI chr 3:108,915,263...108,970,620
Ensembl chr 3:108,915,280...108,967,227

G

catenin alpha-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTNNAL1 mRNA

NCBI chr 5:71,514,340...71,569,431
Ensembl chr 5:71,514,340...71,569,431

G

CTR9 homolog, Paf1/RNA polymerase II complex component

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CTR9 mRNA

NCBI chr 1:165,137,277...165,167,303
Ensembl chr 1:165,137,215...165,167,303

G

cortactin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTN mRNA

NCBI chr 1:199,599,710...199,635,254
Ensembl chr 1:199,599,710...199,635,164

G

CTTNBP2 N-terminal like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CTTNBP2NL mRNA

NCBI chr 2:192,507,963...192,554,548
Ensembl chr 2:192,507,963...192,541,101

G

CXXC finger protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CXXC5 mRNA

NCBI chr18:27,427,591...27,458,579
Ensembl chr18:27,427,230...27,458,673

G

cytochrome b5 reductase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYB5R1 mRNA

NCBI chr13:45,849,017...45,855,458
Ensembl chr13:45,849,091...45,855,458

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

CYP17A1 gene SNP affects the susceptibility to [Phytoestrogens results in increased abundance of 2,3-bis(3'-hydroxybenzyl)butyrolactone]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

decreases activity

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased activity of CYP19A1 protein

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

cytochrome P450, family 2, subfamily r, polypeptide 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of CYP2R1 mRNA

NCBI chr 1:168,749,302...168,798,079
Ensembl chr 1:168,751,038...168,797,759

G

CYFIP related Rac1 interactor B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of CYRIB mRNA

NCBI chr 7:95,633,876...95,760,588
Ensembl chr 7:95,633,876...95,697,686

G

differentiation antagonizing non-protein coding RNA

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DANCR mRNA

NCBI chr14:34,126,956...34,127,936

G

aspartyl-tRNA synthetase 2 (mitochondrial)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DARS2 mRNA

NCBI chr13:73,308,726...73,336,558
Ensembl chr13:73,308,726...73,336,934

G

DBF4-CDC7 kinase regulatory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DBF4 mRNA

NCBI chr 4:25,676,570...25,701,152
Ensembl chr 4:25,676,634...25,701,066

G

drebrin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DBN1 mRNA

NCBI chr17:9,150,608...9,164,982
Ensembl chr17:9,150,659...9,164,984

G

DDB1 and CUL4 associated factor 15

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCAF15 mRNA

NCBI chr19:24,053,925...24,061,277
Ensembl chr19:24,053,925...24,061,277

G

DDB1 and CUL4 associated factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF4 mRNA

NCBI chr 6:103,154,847...103,180,992
Ensembl chr 6:103,154,867...103,180,982

G

DDB1 and CUL4 associated factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

doublecortin-like kinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DCLK1 mRNA

NCBI chr 2:139,417,234...139,710,956
Ensembl chr 2:139,417,163...139,710,956

G

DNA cross-link repair 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1A mRNA

NCBI chr 1:255,569,911...255,589,815
Ensembl chr 1:255,569,919...255,589,678

G

DNA cross-link repair 1B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

DDAH family member 2, ADMA-independent

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DDAH2 mRNA

NCBI chr20:3,761,460...3,764,718
Ensembl chr20:3,761,465...3,764,511

G

damage specific DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:77,185,109...77,207,631

G

DNA damage-induced apoptosis suppressor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDIAS mRNA

NCBI chr 1:146,906,150...146,930,462
Ensembl chr 1:146,906,154...146,930,462

G

DExD-box helicase 39B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DDX39B mRNA

NCBI chr20:3,547,702...3,585,064
Ensembl chr20:3,572,056...3,584,996

G

DENN domain containing 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DENND11 mRNA

NCBI chr 4:69,197,161...69,266,013
Ensembl chr 4:69,198,068...69,228,821

G

DEP domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPDC1 mRNA

NCBI chr 2:248,684,508...248,717,951
Ensembl chr 2:248,684,523...248,717,951

G

DEP domain containing MTOR-interacting protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DEPTOR mRNA

NCBI chr 7:86,514,859...86,668,817
Ensembl chr 7:86,514,988...86,667,773

G

deoxyribose-phosphate aldolase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DERA mRNA

NCBI chr 4:170,663,689...170,742,469
Ensembl chr 4:170,663,665...170,758,865

G

dihydrofolate reductase

increases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of DHFR mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

dehydrogenase/reductase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHRS2 mRNA

NCBI chr15:28,688,881...28,703,646
Ensembl chr15:28,688,940...28,703,644

G

dehydrogenase E1 and transketolase domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DHTKD1 mRNA

NCBI chr17:72,355,201...72,406,725
Ensembl chr17:72,355,201...72,406,723

G

diaphanous-related formin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DIAPH3 mRNA

NCBI chr15:62,543,375...63,013,060
Ensembl chr15:62,543,375...63,012,975

G

disco-interacting protein 2 homolog C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DIP2C mRNA

NCBI chr17:60,647,346...61,032,467
Ensembl chr17:60,649,065...61,032,305

G

dyskerin pseudouridine synthase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DKC1 mRNA

G

DLG associated protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DLGAP5 mRNA

NCBI chr15:20,633,964...20,664,569
Ensembl chr15:20,633,966...20,664,518

G

distal-less homeobox 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DLX2 mRNA

NCBI chr 3:56,370,238...56,373,581
Ensembl chr 3:56,370,483...56,373,597

G

Dmx-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DMXL1 mRNA

NCBI chr18:42,993,292...43,163,457
Ensembl chr18:42,993,340...43,163,456

G

DnaJ heat shock protein family (Hsp40) member A2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJA2 mRNA

NCBI chr19:21,497,792...21,516,904
Ensembl chr19:21,497,729...21,516,901

G

DnaJ heat shock protein family (Hsp40) member B9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNAJB9 mRNA

NCBI chr 6:61,270,385...61,276,795
Ensembl chr 6:61,269,913...61,275,063

G

DnaJ heat shock protein family (Hsp40) member C9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNAJC9 mRNA

NCBI chr15:3,923,842...3,928,118
Ensembl chr15:3,923,268...3,928,118

G

deoxyribonuclease 2, lysosomal

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNASE2 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of DNASE2 mRNA

NCBI chr19:23,244,656...23,247,376
Ensembl chr19:23,244,664...23,247,376

G

dynamin 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DNM1L mRNA

NCBI chr11:84,581,216...84,632,382
Ensembl chr11:84,581,216...84,631,482

G

DNA methyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA replication fork stabilization factor DONSON

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DONSON mRNA

NCBI chr11:30,919,834...30,933,150
Ensembl chr11:30,923,239...30,932,889

G

DNA replication and sister chromatid cohesion 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSCC1 mRNA

NCBI chr 7:86,482,588...86,498,212
Ensembl chr 7:86,482,588...86,498,212

G

DSN1 component of MIS12 kinetochore complex

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DSN1 mRNA

NCBI chr 3:145,652,741...145,668,025
Ensembl chr 3:145,652,737...145,665,856

G

dystrobrevin, alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DTNA mRNA

NCBI chr18:14,687,193...14,944,232
Ensembl chr18:14,587,852...14,944,261

G

dual specificity phosphatase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DUSP1 mRNA

NCBI chr10:16,680,478...16,683,275

G

deoxyuridine triphosphatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DUT mRNA

NCBI chr 3:112,498,864...112,509,994
Ensembl chr 3:112,498,982...112,510,771

G

dynein cytoplasmic 1 light intermediate chain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of DYNC1LI1 mRNA

NCBI chr 8:114,376,649...114,410,297
Ensembl chr 8:114,376,662...114,410,934

G

dynein 2 intermediate chain 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of DYNC2I2 mRNA

NCBI chr 3:13,306,039...13,322,121
Ensembl chr 3:13,306,039...13,322,121

G

E2F transcription factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F2 mRNA

NCBI chr 5:148,399,193...148,422,595
Ensembl chr 5:148,399,642...148,421,217

G

E2F transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of E2F5 mRNA

NCBI chr 2:86,997,331...87,012,908
Ensembl chr 2:86,997,332...87,012,990

G

E2F transcription factor 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F7 mRNA

NCBI chr 7:46,150,533...46,192,739
Ensembl chr 7:46,151,293...46,192,734

G

E2F transcription factor 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of E2F8 mRNA

NCBI chr 1:98,565,717...98,584,265
Ensembl chr 1:98,565,717...98,584,098

G

EBP, cholestenol delta-isomerase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

epithelial cell transforming 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ECT2 mRNA

NCBI chr 2:109,975,813...110,037,911
Ensembl chr 2:109,975,813...110,037,911

G

EGF like repeats and discoidin domains 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EDIL3 mRNA

NCBI chr 2:19,890,396...20,405,028
Ensembl chr 2:19,890,373...20,405,008

G

embryonic ectoderm development

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EED mRNA

NCBI chr 1:143,867,875...143,895,008
Ensembl chr 1:143,867,875...143,894,974

G

eukaryotic translation elongation factor 1 alpha 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EEF1A1 mRNA

NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839

G

EGF containing fibulin extracellular matrix protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFEMP1 mRNA

NCBI chr14:102,610,813...102,690,027
Ensembl chr14:102,610,908...102,690,018

G

EF-hand domain family, member D1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFHD1 mRNA

NCBI chr 9:87,938,259...87,984,917
Ensembl chr 9:87,938,284...87,984,917

G

ephrin A1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNA1 mRNA

NCBI chr 2:174,681,676...174,689,061
Ensembl chr 2:174,681,682...174,690,866

G

ephrin B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EFNB2 mRNA

NCBI chr16:80,783,389...80,827,420
Ensembl chr16:80,783,417...80,824,391

G

early growth response 1

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of EGR1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EGR1 mRNA

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EGR3 mRNA

NCBI chr15:45,150,335...45,156,052
Ensembl chr15:45,150,567...45,154,627

G

E74 like ETS transcription factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ELF5 mRNA

NCBI chr 3:89,808,837...89,836,977
Ensembl chr 3:89,797,880...89,836,973

G

ETS transcription factor ELK1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELK1 mRNA

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

ELOVL fatty acid elongase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL2 mRNA

NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,544,568...23,584,848

G

ELOVL fatty acid elongase 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL6 mRNA

NCBI chr 2:218,063,682...218,174,767
Ensembl chr 2:218,063,804...218,171,186

G

ELOVL fatty acid elongase 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELOVL7 mRNA

NCBI chr 2:39,789,229...39,858,579
Ensembl chr 2:39,789,250...39,856,845

G

elongator acetyltransferase complex subunit 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ELP6 mRNA

NCBI chr 8:110,280,059...110,295,070
Ensembl chr 8:110,279,979...110,295,067

G

ER membrane protein complex subunit 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EMC9 mRNA

NCBI chr15:29,071,881...29,076,098
Ensembl chr15:29,071,883...29,076,098

G

essential meiotic structure-specific endonuclease 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EME1 mRNA

NCBI chr10:79,586,718...79,595,515
Ensembl chr10:79,586,729...79,595,435

G

ectodermal-neural cortex 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENC1 mRNA

NCBI chr 2:28,550,670...28,562,591
Ensembl chr 2:28,550,464...28,562,713

G

endonuclease domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENDOD1 mRNA

NCBI chr 8:11,209,113...11,238,507
Ensembl chr 8:11,211,110...11,238,892

G

enolase superfamily member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ENOSF1 mRNA

NCBI chr 9:113,275,267...113,314,842

G

endosomal transmembrane epsin interactor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ENTREP1 mRNA

NCBI chr 1:221,592,500...221,646,603
Ensembl chr 1:221,592,503...221,646,758

G

erythrocyte membrane protein band 4.1 like 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPB41L5 mRNA

NCBI chr13:30,670,792...30,770,213
Ensembl chr13:30,669,764...30,768,360

G

Eph receptor A4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EPHA4 mRNA

NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139

G

epidermal growth factor receptor pathway substrate 15-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EPS15L1 mRNA

NCBI chr16:17,426,345...17,501,677
Ensembl chr16:17,426,421...17,501,677

G

ERCC excision repair 6 like, spindle assembly checkpoint helicase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERCC6L mRNA

NCBI chr X:67,245,414...67,261,222
Ensembl chr X:67,245,414...67,280,756

G

ERI1 exoribonuclease family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ERI2 mRNA

NCBI chr 1:174,140,831...174,168,757
Ensembl chr 1:174,141,993...174,168,665

G

ERBB receptor feedback inhibitor 1

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of ERRFI1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ERRFI1 mRNA

NCBI chr 5:161,323,981...161,337,289
Ensembl chr 5:161,323,998...161,337,282

G

extra spindle pole bodies like 1, separase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ESPL1 mRNA

NCBI chr 7:133,424,027...133,450,984
Ensembl chr 7:133,424,130...133,450,984

G

exonuclease 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EXO1 mRNA

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:87,809,810...87,834,654

G

exocyst complex component 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXOC2 mRNA

NCBI chr17:33,506,289...33,698,246
Ensembl chr17:33,506,338...33,693,289

G

exostosin glycosyltransferase 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EXT1 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of EXT1 mRNA

NCBI chr 7:84,375,769...84,654,625
Ensembl chr 7:84,375,784...84,655,357

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of EZH2 mRNA

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

G

ezrin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of EZR mRNA

NCBI chr 1:46,967,961...47,011,505
Ensembl chr 1:46,967,658...47,011,505

G

F2R like trypsin receptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of F2RL1 mRNA

NCBI chr 2:26,772,274...26,785,226
Ensembl chr 2:26,772,278...26,785,226

G

family with sequence similarity 107, member B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM107B mRNA

NCBI chr17:74,478,608...74,685,027
Ensembl chr17:74,478,608...74,684,989

G

family with sequence similarity 110, member B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM110B mRNA

NCBI chr 5:18,789,362...18,929,647
Ensembl chr 5:18,789,389...18,929,828

G

FAM111 trypsin like peptidase A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FAM111A mRNA

NCBI chr 1:209,640,865...209,656,551
Ensembl chr 1:209,640,953...209,656,547

G

family with sequence similarity 149, member B1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM149B1 mRNA

NCBI chr15:3,929,190...3,967,140
Ensembl chr15:3,929,190...3,966,997

G

family with sequence similarity 43, member A

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of FAM43A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FAM43A mRNA

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:70,128,253...70,131,401

G

FA complementation group D2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCD2 mRNA

NCBI chr 4:146,679,014...146,743,422
Ensembl chr 4:146,679,179...146,743,412

G

FA complementation group G

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCG mRNA

NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:57,231,685...57,240,029

G

FA complementation group I

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCI mRNA

NCBI chr 1:133,327,264...133,383,661
Ensembl chr 1:133,327,297...133,383,640

G

FA complementation group L

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FANCL mRNA

NCBI chr14:100,249,733...100,317,958
Ensembl chr14:100,248,875...100,314,255

G

F-box protein 38

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FBXO38 mRNA

NCBI chr18:55,956,950...56,004,013
Ensembl chr18:55,956,959...56,003,961

G

F-box protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FBXO5 mRNA

NCBI chr 1:42,196,068...42,202,437
Ensembl chr 1:42,196,068...42,202,437

G

Fc mu receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FCMR mRNA

NCBI chr13:42,337,363...42,351,706
Ensembl chr13:42,337,414...42,351,653

G

farnesyl diphosphate farnesyl transferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FDFT1 mRNA

NCBI chr15:37,412,143...37,440,198
Ensembl chr15:37,412,146...37,440,287

G

flap structure-specific endonuclease 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FEN1 mRNA

NCBI chr 1:206,845,126...206,849,821
Ensembl chr 1:206,844,884...206,850,003

G

FERM domain containing kindlin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FERMT2 mRNA

NCBI chr15:18,682,927...18,751,959
Ensembl chr15:18,682,927...18,751,811

G

FGF1 intracellular binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIBP mRNA

NCBI chr 1:202,768,065...202,772,405
Ensembl chr 1:202,768,078...202,772,399

G

fidgetin-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIGNL1 mRNA

NCBI chr14:86,368,670...86,381,728
Ensembl chr14:86,368,675...86,377,455

G

filamin A interacting protein 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FILIP1L mRNA

NCBI chr11:42,937,353...43,177,085
Ensembl chr11:42,940,467...43,177,415

G

FIGNL1 interacting regulator of recombination and mitosis

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FIRRM mRNA

NCBI chr13:76,301,914...76,345,842
Ensembl chr13:76,301,918...76,345,804

G

FKBP prolyl isomerase 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP11 mRNA

NCBI chr 7:129,871,870...129,877,760
Ensembl chr 7:129,871,870...129,875,303

G

FKBP prolyl isomerase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FKBP4 mRNA

NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833

G

folliculin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FLCN mRNA

NCBI chr10:44,588,621...44,607,808
Ensembl chr10:44,588,624...44,607,769

G

formin binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1 mRNA

NCBI chr 3:14,309,067...14,424,378
Ensembl chr 3:14,309,640...14,424,881

G

formin binding protein 1-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FNBP1L mRNA

NCBI chr 2:210,647,241...210,748,203
Ensembl chr 2:210,647,246...210,738,455

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

forkhead box M1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of FOXM1 mRNA

NCBI chr 4:161,639,538...161,652,012
Ensembl chr 4:161,638,816...161,650,684

G

forkhead box O3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXO3 mRNA

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

forkhead box P2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FOXP2 mRNA

NCBI chr 4:43,133,827...43,712,442
Ensembl chr 4:43,133,912...43,711,683

G

FERM domain containing 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FRMD6 mRNA

NCBI chr 6:89,345,983...89,419,579
Ensembl chr 6:89,346,035...89,419,579

G

fascin actin-bundling protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FSCN1 mRNA

NCBI chr12:11,597,042...11,610,183
Ensembl chr12:11,597,048...11,610,211

G

FYVE and coiled-coil domain autophagy adaptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of FYCO1 mRNA

NCBI chr 8:123,412,105...123,479,315
Ensembl chr 8:123,412,112...123,479,021

G

G2/M-phase specific E3 ubiquitin protein ligase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G2E3 mRNA

NCBI chr 6:68,763,847...68,795,305
Ensembl chr 6:68,764,185...68,793,924

G

G3BP stress granule assembly factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of G3BP2 mRNA

NCBI chr14:15,932,403...16,020,555
Ensembl chr14:15,987,417...16,020,548

G

GA binding protein transcription factor subunit beta 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GABPB2 mRNA

NCBI chr 2:182,755,304...182,795,368
Ensembl chr 2:182,761,359...182,795,109

G

growth arrest and DNA-damage-inducible, alpha

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of GADD45A mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

galactosamine (N-acetyl)-6-sulfatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNS mRNA

NCBI chr19:50,628,639...50,662,477
Ensembl chr19:50,628,552...50,662,246

G

polypeptide N-acetylgalactosaminyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT1 mRNA

NCBI chr18:15,489,015...15,568,849
Ensembl chr18:15,489,020...15,568,245

G

polypeptide N-acetylgalactosaminyltransferase 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT10 mRNA

NCBI chr10:41,821,216...41,967,618
Ensembl chr10:41,820,158...41,967,013

G

polypeptide N-acetylgalactosaminyltransferase 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GALNT7 mRNA

NCBI chr16:32,578,643...32,703,189
Ensembl chr16:32,578,690...32,702,690

G

glucosidase II alpha subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GANAB mRNA

NCBI chr 1:205,793,910...205,813,704
Ensembl chr 1:205,793,895...205,813,695

G

growth arrest-specific 2 like 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GAS2L3 mRNA

NCBI chr 7:23,803,578...23,836,816
Ensembl chr 7:23,806,310...23,836,411

G

GATA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

guanylate binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GBP2 mRNA

NCBI chr 2:231,332,488...231,348,573
Ensembl chr 2:231,332,284...231,348,571

G

GTP cyclohydrolase I feedback regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GCHFR mRNA

NCBI chr 3:106,158,046...106,162,080
Ensembl chr 3:106,159,394...106,162,080

G

growth differentiation factor 15

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDF15 mRNA

NCBI chr16:18,804,457...18,808,043
Ensembl chr16:18,805,239...18,808,055

G

glycerophosphodiester phosphodiesterase domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GDPD3 mRNA

NCBI chr 1:181,373,505...181,383,063
Ensembl chr 1:181,366,626...181,383,063

G

gem (nuclear organelle) associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GEMIN2 mRNA

NCBI chr 6:76,706,424...76,721,154
Ensembl chr 6:76,707,523...76,721,153

G

GDNF family receptor alpha 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GFRA1 mRNA

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:257,321,742...257,551,473

G

gamma-glutamyl cyclotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGCT mRNA

NCBI chr 4:84,122,921...84,129,327
Ensembl chr 4:84,123,118...84,129,277

G

gamma-glutamyl hydrolase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GGH mRNA

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

GINS complex subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS1 mRNA

NCBI chr 3:139,724,513...139,745,930
Ensembl chr 3:139,724,490...139,745,936

G

GINS complex subunit 2

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS2 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of GINS2 mRNA

NCBI chr19:48,626,770...48,639,523
Ensembl chr19:48,626,770...48,639,339

G

GINS complex subunit 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS3 mRNA

NCBI chr19:9,420,085...9,428,621
Ensembl chr19:9,420,086...9,428,687

G

GINS complex subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GINS4 mRNA

NCBI chr16:68,787,572...68,799,938
Ensembl chr16:68,767,339...68,802,273

G

GLE1 RNA export mediator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GLE1 mRNA

NCBI chr 3:13,209,312...13,237,018
Ensembl chr 3:13,209,322...13,237,379

G

geminin, DNA replication inhibitor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMNN mRNA

NCBI chr17:40,301,771...40,310,054
Ensembl chr17:40,301,808...40,310,054

G

guanine monophosphate synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GMPS mRNA

NCBI chr 2:148,441,369...148,491,908
Ensembl chr 2:148,435,643...148,485,875

G

GNAS complex locus

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of GNAS mRNA

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

golgin A2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GOLGA2 mRNA

NCBI chr 3:15,583,862...15,604,279
Ensembl chr 3:15,584,039...15,604,279

G

glutamic-oxaloacetic transaminase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GOT1 mRNA

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycosylphosphatidylinositol anchor attachment 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAA1 mRNA

NCBI chr 7:108,051,896...108,055,479
Ensembl chr 7:108,051,861...108,055,484

G

glycerol-3-phosphate acyltransferase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPAT4 mRNA

NCBI chr16:68,819,031...68,852,903
Ensembl chr16:68,819,079...68,852,901

G

G protein-coupled receptor, class C, group 5, member A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5A mRNA

NCBI chr 4:167,903,542...167,922,276
Ensembl chr 4:167,903,542...167,922,260

G

G protein-coupled receptor, class C, group 5, member C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GPRC5C mRNA

NCBI chr10:99,886,900...99,908,928
Ensembl chr10:99,887,077...99,908,926

G

G-protein signaling modulator 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GPSM2 mRNA

NCBI chr 2:196,327,149...196,375,322
Ensembl chr 2:196,327,149...196,375,154

G

GRAM domain containing 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRAMD1A mRNA

NCBI chr 1:86,367,001...86,393,348
Ensembl chr 1:86,367,001...86,393,336

G

growth regulating estrogen receptor binding 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GREB1 mRNA

NCBI chr 6:39,440,522...39,562,364
Ensembl chr 6:39,440,504...39,581,633

G

grainyhead-like transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GRHL3 mRNA

NCBI chr 5:147,774,161...147,806,291
Ensembl chr 5:147,774,160...147,806,160

G

GTF2I repeat domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GTF2IRD1 mRNA

NCBI chr12:22,254,113...22,361,052
Ensembl chr12:22,254,221...22,361,040

G

G-2 and S-phase expressed 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of GTSE1 mRNA

NCBI chr 7:116,949,997...116,966,826
Ensembl chr 7:116,950,053...116,966,806

G

GULP PTB domain containing engulfment adaptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of GULP1 mRNA

NCBI chr 9:46,622,699...46,899,005
Ensembl chr 9:46,622,669...46,899,005

G

H1.2 linker histone, cluster member

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H1-2 mRNA

NCBI chr17:41,391,106...41,392,597
Ensembl chr17:41,388,477...41,392,635

G

H2A clustered histone 25

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC25 mRNA

NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874

G

H2A.X variant histone

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AX mRNA

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2A.Z variant histone 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ1 mRNA

NCBI chr 2:226,355,668...226,357,984
Ensembl chr 2:226,355,708...226,358,485

G

H2A.Z variant histone 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of H2AZ2 mRNA

NCBI chr14:81,293,304...81,312,209
Ensembl chr14:81,293,299...81,312,144

G

H2B clustered histone 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC8 mRNA

NCBI chr17:42,708,658...42,709,408

G

H2B clustered histone 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

H3.3 histone B

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of H3-3B mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H3-3B mRNA

NCBI chr10:101,256,484...101,258,716
Ensembl chr10:101,256,480...101,258,709

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HADH mRNA

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

HAUS augmin-like complex, subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS1 mRNA

NCBI chr18:71,275,417...71,286,626
Ensembl chr18:71,273,537...71,286,660

G

HAUS augmin-like complex, subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HAUS4 mRNA

NCBI chr15:27,994,530...28,006,147
Ensembl chr15:27,994,532...28,005,938

G

heme binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HEBP1 mRNA

NCBI chr 4:167,974,316...168,003,854
Ensembl chr 4:167,974,319...168,003,854

G

helicase, lymphoid specific

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HELLS mRNA

NCBI chr 1:236,701,704...236,748,239
Ensembl chr 1:236,701,758...236,746,844

G

helicase with zinc finger 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HELZ2 mRNA

NCBI chr 3:168,338,813...168,353,219
Ensembl chr 3:168,338,813...168,353,159

G

HECT and RLD domain containing E3 ubiquitin protein ligase family member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HERC1 mRNA

NCBI chr 8:66,857,169...67,070,318
Ensembl chr 8:66,856,935...67,070,312

G

hes family bHLH transcription factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HES1 mRNA

NCBI chr11:70,705,763...70,708,176
Ensembl chr11:70,705,764...70,708,192

G

HIRA interacting protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HIRIP3 mRNA

NCBI chr 1:181,472,537...181,475,082
Ensembl chr 1:181,472,056...181,475,079

G

histone cluster 1 H2A family member F

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC8 mRNA

NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796

G

histone cluster 1 H2A family like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

histone cluster 1, H2bc

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC21 mRNA

NCBI chr17:42,692,335...42,696,601
Ensembl chr17:42,694,723...42,696,642

G

histone cluster 1 H2B family member D

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of H2BC5 mRNA

NCBI chr17:42,792,887...42,793,268

G

Holliday junction recognition protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HJURP mRNA

NCBI chr 9:88,853,379...88,867,730
Ensembl chr 9:88,853,386...88,867,728

G

high mobility group AT-hook 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGA1 mRNA

NCBI chr20:5,611,088...5,618,755
Ensembl chr20:5,611,694...5,618,752

G

high mobility group box 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGB1 mRNA

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

high mobility group box 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGB2 mRNA

NCBI chr16:32,710,651...32,713,230
Ensembl chr16:32,710,658...32,713,140

G

high mobility group nucleosomal binding domain 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMGN3 mRNA

NCBI chr 8:84,022,493...84,059,329
Ensembl chr 8:84,022,495...84,062,976

G

hyaluronan-mediated motility receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HMMR mRNA

NCBI chr10:25,132,933...25,163,029
Ensembl chr10:25,132,977...25,163,060

G

heterogeneous nuclear ribonucleoprotein H1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HNRNPH1 mRNA

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

homeo box C6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HOXC6 mRNA

NCBI chr 7:134,138,017...134,148,899
Ensembl chr 7:134,135,502...134,148,392

G

hypoxanthine phosphoribosyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HPRT1 mRNA

NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154

G

heparan sulfate 6-O-sulfotransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of HS6ST2 mRNA

NCBI chr X:130,966,547...131,261,629
Ensembl chr X:130,968,385...131,261,492

G

hydroxysteroid (17-beta) dehydrogenase 1

decreases activity

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased activity of HSD17B1 protein

NCBI chr10:86,009,728...86,011,928
Ensembl chr10:86,009,728...86,011,927

G

hydroxysteroid (17-beta) dehydrogenase 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSD17B6 mRNA

NCBI chr 7:422,466...442,008
Ensembl chr 7:422,480...442,425

G

heat shock protein family A (Hsp70) member 4 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HSPA4L mRNA

NCBI chr 2:123,740,384...123,793,088
Ensembl chr 2:123,740,384...123,793,084

G

HYLS1, centriolar and ciliogenesis associated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of HYLS1 mRNA

NCBI chr 8:33,912,692...33,921,760
Ensembl chr 8:33,912,692...33,921,760

G

islet cell autoantigen 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ICA1 mRNA

NCBI chr 4:36,656,475...36,804,705
Ensembl chr 4:36,656,475...36,804,298

G

intercellular adhesion molecule 1

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of ICAM1 protein

NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438

G

interactor of little elongation complex ELL subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ICE1 mRNA

NCBI chr 1:32,640,372...32,682,669
Ensembl chr 1:32,640,407...32,679,898

G

isoprenylcysteine carboxyl methyltransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ICMT mRNA

NCBI chr 5:162,804,368...162,811,129
Ensembl chr 5:162,804,368...162,811,128

G

inhibitor of DNA binding 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ID3 mRNA

NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349

G

iduronate 2-sulfatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IDS mRNA

NCBI chr X:149,025,976...149,046,641
Ensembl chr X:149,025,976...149,046,663

G

immediate early response 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IER2 mRNA

NCBI chr19:23,494,551...23,496,075
Ensembl chr19:23,494,184...23,499,211

G

immediate early response 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IER5 mRNA

NCBI chr13:67,270,134...67,272,226
Ensembl chr13:67,270,135...67,272,227

G

interferon-induced protein 44-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFI44L mRNA

NCBI chr 2:240,668,742...240,706,425
Ensembl chr 2:240,668,713...240,706,359

G

interferon-induced protein with tetratricopeptide repeats 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFIT2 mRNA

NCBI chr 1:232,102,570...232,108,638
Ensembl chr 1:232,102,570...232,108,635

G

interferon-related developmental regulator 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IFRD2 mRNA

NCBI chr 8:108,260,969...108,266,191
Ensembl chr 8:108,260,969...108,266,194

G

intraflagellar transport 122

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT122 mRNA

NCBI chr 4:148,905,031...148,975,458
Ensembl chr 4:148,905,046...148,975,458

G

intraflagellar transport 20

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT20 mRNA

NCBI chr10:63,432,597...63,438,125
Ensembl chr10:63,432,633...63,438,124

G

intraflagellar transport 43

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IFT43 mRNA

NCBI chr 6:105,729,734...105,806,257
Ensembl chr 6:105,729,792...105,806,257

G

insulin-like growth factor binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFBP2 mRNA

NCBI chr 9:74,415,574...74,442,945
Ensembl chr 9:74,415,546...74,442,937

G

insulin-like growth factor binding protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225

G

insulin-like growth factor binding protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IGFBP5 mRNA

NCBI chr 9:74,452,371...74,464,953
Ensembl chr 9:74,448,382...74,465,156

G

IGF-like family receptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IGFLR1 mRNA

NCBI chr 1:85,818,428...85,821,032
Ensembl chr 1:85,816,326...85,821,030

G

interleukin 1 beta

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor type 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IL1R1 mRNA

NCBI chr 9:42,504,917...42,580,958
Ensembl chr 9:42,504,735...42,579,937

G

interleukin 20

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IL20 mRNA

NCBI chr13:42,380,981...42,384,625
Ensembl chr13:42,380,981...42,384,625

G

interleukin enhancer binding factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ILF2 mRNA

NCBI chr 2:175,952,174...175,971,191
Ensembl chr 2:175,952,186...175,971,337

G

ilvB acetolactate synthase like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ILVBL mRNA

NCBI chr 7:11,039,870...11,049,924
Ensembl chr 7:11,039,871...11,049,924

G

inner centromere protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INCENP mRNA

NCBI chr 1:206,520,655...206,550,575
Ensembl chr 1:206,523,380...206,553,265

G

inhibin subunit beta B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of INHBB mRNA

NCBI chr13:30,530,860...30,536,566
Ensembl chr13:30,530,860...30,537,832

G

INO80 complex subunit E

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INO80E mRNA

NCBI chr 1:181,461,406...181,472,059
Ensembl chr 1:181,461,408...181,472,469

G

insulin induced gene 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of INSIG1 mRNA

NCBI chr 4:7,315,494...7,323,972
Ensembl chr 4:7,315,495...7,323,952

G

inositol hexakisphosphate kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IP6K2 mRNA

NCBI chr 8:109,483,843...109,510,172
Ensembl chr 8:109,484,310...109,510,166

G

IQ motif containing K

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IQCK mRNA

NCBI chr 1:173,199,308...173,316,982
Ensembl chr 1:173,199,316...173,316,984

G

IQ motif containing GTPase activating protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of IQGAP3 mRNA

NCBI chr 2:173,542,151...173,583,956
Ensembl chr 2:173,542,110...173,583,956

G

interferon regulatory factor 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRF6 mRNA

NCBI chr13:104,672,179...104,691,386
Ensembl chr13:104,672,179...104,691,386

G

interferon regulatory factor 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRF9 mRNA

NCBI chr15:29,095,474...29,101,924
Ensembl chr15:29,095,789...29,101,236

G

insulin receptor substrate 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of IRS2 mRNA

NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482

G

inositol-3-phosphate synthase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ISYNA1 mRNA

NCBI chr16:18,839,143...18,841,979
Ensembl chr16:18,839,145...18,841,979

G

integrin subunit alpha 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha E

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ITGAE mRNA

NCBI chr10:57,704,813...57,764,093
Ensembl chr10:57,591,753...57,764,093
Ensembl chr10:57,591,753...57,764,093

G

integrin subunit alpha L

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of ITGAL protein

NCBI chr 1:181,918,183...181,955,735
Ensembl chr 1:181,918,183...181,955,732

G

integrin subunit beta 2

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of ITGB2 protein

NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600

G

integrin subunit beta 3 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ITGB3BP mRNA

NCBI chr 5:114,460,217...114,525,538
Ensembl chr 5:114,460,221...114,525,704

G

inositol 1,4,5-trisphosphate receptor, type 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

jagged canonical Notch ligand 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JAG1 mRNA

NCBI chr 3:124,406,783...124,442,220
Ensembl chr 3:124,406,794...124,442,209

G

junction mediating and regulatory protein, p53 cofactor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JMY mRNA

NCBI chr 2:24,662,104...24,730,955
Ensembl chr 2:24,668,854...24,731,006

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

JunB proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of JUNB mRNA

NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035

G

lysine demethylase 4B

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of KDM4B mRNA

NCBI chr 9:1,158,737...1,237,233
Ensembl chr 9:1,158,752...1,236,543

G

lysine demethylase 5A

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of KDM5A mRNA

NCBI chr 4:153,565,909...153,643,912
Ensembl chr 4:153,565,846...153,642,422

G

lysine demethylase 5B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KDM5B mRNA

NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872

G

kinase insert domain receptor

multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone inhibits the reaction [Estradiol results in increased expression of KDR protein]

NCBI chr14:32,217,871...32,261,018
Ensembl chr14:32,217,871...32,261,018

G

kinase D-interacting substrate 220

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIDINS220 mRNA

NCBI chr 6:41,618,207...41,706,990
Ensembl chr 6:41,618,294...41,703,256

G

kinesin family member 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF11 mRNA

NCBI chr 1:235,124,371...235,176,760
Ensembl chr 1:235,124,316...235,176,766

G

kinesin family member 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF14 mRNA

NCBI chr13:47,926,975...47,990,598
Ensembl chr13:47,927,044...47,989,164

G

kinesin family member 18A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF18A mRNA

NCBI chr 3:95,764,388...95,824,756
Ensembl chr 3:95,764,388...95,824,582

G

kinesin family member 20A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF20A mRNA

NCBI chr18:26,230,294...26,238,780
Ensembl chr18:26,230,230...26,238,780

G

kinesin family member 2C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIF2C mRNA

NCBI chr 5:130,637,347...130,662,680
Ensembl chr 5:130,637,347...130,662,637

G

kinesin family member 5C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KIF5C mRNA

NCBI chr 3:34,032,082...34,185,597
Ensembl chr 3:34,032,105...34,182,413

G

kinesin family member C1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KIFC1 mRNA

NCBI chr20:4,998,832...5,017,107
Ensembl chr20:4,999,047...5,017,105

G

KLF transcription factor 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF12 mRNA

NCBI chr15:76,628,778...77,062,000
Ensembl chr15:76,637,654...77,062,056

G

KLF transcription factor 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

KLF transcription factor 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLF9 mRNA

NCBI chr 1:220,700,108...220,725,110
Ensembl chr 1:220,700,108...220,725,037

G

kelch domain containing 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KLHDC3 mRNA

NCBI chr 9:14,302,345...14,308,736
Ensembl chr 9:14,302,354...14,308,736

G

kelch-like family member 24

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLHL24 mRNA

NCBI chr11:80,843,621...80,877,649
Ensembl chr11:80,846,755...80,877,636

G

kelch-like family member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KLHL5 mRNA

NCBI chr14:43,144,254...43,206,192
Ensembl chr14:43,144,257...43,184,238

G

lysine methyltransferase 2E

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KMT2E mRNA

NCBI chr 4:11,658,218...11,727,373
Ensembl chr 4:11,658,979...11,727,373

G

kinetochore-localized astrin/SPAG5 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of KNSTRN mRNA

NCBI chr 3:105,800,762...105,820,555
Ensembl chr 3:105,800,954...105,820,715

G

karyopherin subunit alpha 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KPNA4 mRNA

NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081

G

keratin 80

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of KRT80 mRNA

NCBI chr 7:132,463,216...132,485,134
Ensembl chr 7:132,463,218...132,485,508

G

L1 cell adhesion molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of L1CAM mRNA

NCBI chr X:151,597,270...151,623,776
Ensembl chr X:151,597,277...151,623,857

G

L-2-hydroxyglutarate dehydrogenase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of L2HGDH mRNA

NCBI chr 6:88,164,429...88,205,585
Ensembl chr 6:88,164,440...88,205,578

G

L antigen family, member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LAGE3 mRNA

NCBI chr X:152,138,209...152,139,632
Ensembl chr X:152,138,218...152,139,632

G

La ribonucleoprotein 6, translational regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LARP6 mRNA

NCBI chr 8:61,183,744...61,205,548
Ensembl chr 8:61,184,116...61,205,535

G

leucine carboxyl methyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LCMT2 mRNA

NCBI chr 3:108,099,960...108,102,084
Ensembl chr 3:108,099,961...108,102,084

G

low density lipoprotein receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

leptin receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LEPR mRNA

NCBI chr 5:116,294,409...116,477,904
Ensembl chr 5:116,289,823...116,475,908

G

galectin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of LGALS1 mRNA

NCBI chr 7:110,485,239...110,488,345
Ensembl chr 7:110,481,392...110,488,345

G

DNA ligase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LIG1 mRNA

NCBI chr 1:74,165,688...74,204,400
Ensembl chr 1:74,165,842...74,204,413

G

lamin B1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LMNB1 mRNA

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

lamin B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LMNB2 mRNA

NCBI chr 7:8,792,628...8,808,665
Ensembl chr 7:8,789,314...8,808,665

G

leucine-rich repeats and immunoglobulin-like domains 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LRIG1 mRNA

NCBI chr 4:127,130,899...127,230,956
Ensembl chr 4:127,130,898...127,231,513

G

leucine rich repeat protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LRR1 mRNA

NCBI chr 6:87,643,195...87,651,894
Ensembl chr 6:87,643,217...87,651,894

G

LSM2 homolog, U6 small nuclear RNA and mRNA degradation associated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of LSM2 mRNA

NCBI chr20:3,843,467...3,847,217
Ensembl chr20:3,843,466...3,847,266

G

mitotic arrest deficient 2 like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAD2L1 mRNA

NCBI chr 4:95,906,692...95,918,885
Ensembl chr 4:95,906,817...95,913,470

G

MAF bZIP transcription factor F

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

membrane associated guanylate kinase, WW and PDZ domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAGI1 mRNA

NCBI chr 4:126,205,663...126,811,354
Ensembl chr 4:126,206,816...126,811,691

G

microtubule-associated protein 1B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP1B mRNA

NCBI chr 2:30,817,261...30,910,458
Ensembl chr 2:30,817,261...30,910,317

G

mitogen-activated protein kinase kinase kinase kinase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MAP4K4 mRNA

NCBI chr 9:42,200,708...42,326,708
Ensembl chr 9:42,200,278...42,326,698

G

mitogen activated protein kinase 1

multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

microtubule associated serine/threonine kinase family member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAST4 mRNA

NCBI chr 2:33,893,241...34,483,682
Ensembl chr 2:33,894,436...34,483,723

G

microtubule associated serine/threonine kinase-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MASTL mRNA

NCBI chr17:85,250,512...85,287,479
Ensembl chr17:85,251,997...85,287,353

G

matrilin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MATN3 mRNA

NCBI chr 6:31,748,517...31,768,564
Ensembl chr 6:31,748,474...31,768,101

G

MYC associated zinc finger protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MAZ mRNA

NCBI chr 1:181,629,742...181,635,193
Ensembl chr 1:181,629,729...181,650,408

G

Mab-21 domain containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MB21D2 mRNA

NCBI chr11:71,825,748...71,924,770
Ensembl chr11:71,825,748...71,924,769

G

melanoma cell adhesion molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCAM mRNA

NCBI chr 8:44,479,391...44,487,575
Ensembl chr 8:44,479,376...44,487,571

G

minichromosome maintenance 10 replication initiation factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM10 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of MCM10 mRNA

NCBI chr17:73,263,788...73,288,346
Ensembl chr17:73,266,095...73,287,364

G

minichromosome maintenance complex component 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM2 mRNA

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

minichromosome maintenance complex component 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:23,219,169...23,237,314

G

minichromosome maintenance complex component 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM4 mRNA

NCBI chr11:85,258,443...85,272,144
Ensembl chr11:85,258,443...85,272,144

G

minichromosome maintenance complex component 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM5 mRNA

NCBI chr19:13,483,030...13,504,389
Ensembl chr19:13,483,066...13,504,389

G

minichromosome maintenance complex component 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM6 mRNA

NCBI chr13:39,826,745...39,851,937
Ensembl chr13:39,826,763...39,851,960

G

minichromosome maintenance complex component 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:17,042,212...17,050,063

G

minichromosome maintenance 8 homologous recombination repair factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCM8 mRNA

NCBI chr 3:120,086,741...120,117,008
Ensembl chr 3:120,086,763...120,117,008

G

mitochondrial calcium uniporter dominant negative subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MCUB mRNA

NCBI chr 2:218,479,301...218,549,594
Ensembl chr 2:218,479,301...218,549,593

G

mediator of DNA damage checkpoint 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MDC1 mRNA

NCBI chr20:2,893,693...2,912,394
Ensembl chr20:2,895,505...2,910,240

G

male-enhanced antigen 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MEA1 mRNA

NCBI chr 9:14,300,283...14,304,130
Ensembl chr 9:14,293,446...14,302,060

G

MYST/Esa1-associated factor 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEAF6 mRNA

NCBI chr 5:137,344,681...137,369,703
Ensembl chr 5:137,344,380...137,370,014

G

myocyte enhancer factor 2a

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MEF2A mRNA

NCBI chr 1:120,847,874...120,982,488
Ensembl chr 1:120,850,080...120,981,948

G

maternal embryonic leucine zipper kinase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MELK mRNA

NCBI chr 5:58,540,393...58,600,562
Ensembl chr 5:58,540,449...58,600,937

G

methylphosphate capping enzyme

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MEPCE mRNA

NCBI chr12:18,911,796...18,916,515
Ensembl chr12:18,911,796...18,916,514

G

methionyl aminopeptidase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of METAP2 mRNA

NCBI chr 7:28,412,429...28,440,458
Ensembl chr 7:28,411,608...28,440,434

G

alpha-1,3-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MGAT4B mRNA

NCBI chr10:34,548,918...34,559,229
Ensembl chr10:34,549,433...34,559,229

G

monoglyceride lipase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MGLL mRNA

NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179

G

matrix Gla protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MGP mRNA

NCBI chr 4:169,766,290...169,769,612
Ensembl chr 4:169,766,279...169,769,667

G

microRNA 21

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MIR21 mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

MIS18 binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MIS18BP1 mRNA

NCBI chr 6:83,182,497...83,231,978
Ensembl chr 6:83,182,499...83,231,383

G

marker of proliferation Ki-67

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MKI67 mRNA

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

MAPK interacting serine/threonine kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MKNK2 mRNA

NCBI chr 7:9,039,771...9,050,832
Ensembl chr 7:9,039,728...9,050,827

G

mutL homolog 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MLH1 mRNA

NCBI chr 8:111,196,468...111,233,721
Ensembl chr 8:111,196,468...111,233,617

G

modulator of apoptosis 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MOAP1 mRNA

NCBI chr 6:121,882,565...121,884,500
Ensembl chr 6:121,882,366...121,898,643

G

M-phase phosphoprotein 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MPHOSPH9 mRNA

NCBI chr12:32,275,449...32,346,097
Ensembl chr12:32,275,558...32,342,392

G

MRE11 homolog, double strand break repair nuclease

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRE11 mRNA

NCBI chr 8:11,618,876...11,680,451
Ensembl chr 8:11,632,354...11,678,279

G

mitochondrial rRNA methyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRM2 mRNA

NCBI chr12:14,309,556...14,314,759
Ensembl chr12:14,251,941...14,314,118

G

mitochondrial ribosomal protein L37

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPL37 mRNA

NCBI chr 5:121,827,892...121,846,187
Ensembl chr 5:121,829,111...121,846,176

G

mitochondrial ribosomal protein S26

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPS26 mRNA

NCBI chr 3:117,769,220...117,770,883
Ensembl chr 3:117,769,100...117,770,885

G

mitochondrial ribosomal protein S27

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MRPS27 mRNA

NCBI chr 2:30,740,007...30,808,577
Ensembl chr 2:30,740,033...30,808,577

G

mutS homolog 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MSH6 mRNA

NCBI chr 6:6,562,631...6,579,995
Ensembl chr 6:6,562,632...6,579,956

G

mature T-cell proliferation 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTCP1 mRNA

NCBI chr18:126,189...130,123

G

mitochondrial fission process 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTFP1 mRNA

NCBI chr14:78,968,434...78,972,274
Ensembl chr14:78,968,442...78,972,274

G

methylenetetrahydrofolate dehydrogenase, cyclohydrolase and formyltetrahydrofolate synthetase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTHFD1 mRNA

NCBI chr 6:94,977,862...95,045,375
Ensembl chr 6:94,977,862...95,045,372

G

myotubularin related protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MTMR4 mRNA

NCBI chr10:72,393,411...72,416,342
Ensembl chr10:72,392,551...72,416,342

G

microtubule associated scaffold protein 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MTUS1 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of MTUS1 mRNA

NCBI chr16:51,202,497...51,347,794
Ensembl chr16:51,253,562...51,347,793

G

major vault protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MVP mRNA

NCBI chr 1:181,594,734...181,622,336
Ensembl chr 1:181,594,734...181,622,380

G

Max dimerization protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MXD4 mRNA

NCBI chr14:76,562,105...76,576,224
Ensembl chr14:76,561,774...76,576,221

G

MYB proto-oncogene, transcription factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYB mRNA

NCBI chr 1:15,939,771...15,973,367
Ensembl chr 1:15,939,761...15,973,057

G

MYB proto-oncogene like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYBL2 mRNA

NCBI chr 3:151,705,254...151,733,714
Ensembl chr 3:151,705,288...151,733,708

G

Myc binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MYCBP mRNA

NCBI chr 5:136,135,955...136,143,163
Ensembl chr 5:136,135,931...136,145,616

G

myosin regulatory light chain interacting protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYLIP mRNA

NCBI chr17:19,286,649...19,308,295
Ensembl chr17:19,286,650...19,308,295

G

myosin Ib

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO1B mRNA

NCBI chr 9:49,690,043...49,852,373
Ensembl chr 9:49,690,086...49,850,798

G

myosin VA

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO5A mRNA

NCBI chr 8:75,811,985...75,980,049
Ensembl chr 8:75,812,412...75,975,918

G

myosin Vb

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO5B mRNA

NCBI chr18:68,038,759...68,341,568
Ensembl chr18:68,038,759...68,338,745

G

myosin VI

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of MYO6 mRNA

NCBI chr 8:81,087,157...81,242,022
Ensembl chr 8:81,087,139...81,239,292

G

mitotic spindle organizing protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of MZT1 mRNA

NCBI chr15:75,787,281...75,797,589
Ensembl chr15:75,786,994...75,797,589

G

Nedd4 binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of N4BP1 mRNA

NCBI chr19:20,222,811...20,273,570
Ensembl chr19:20,222,776...20,273,570

G

N(alpha)-acetyltransferase 50, NatE catalytic subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NAA50 mRNA

NCBI chr11:56,538,366...56,560,842
Ensembl chr11:56,538,366...56,560,842

G

nanos C2HC-type zinc finger 1

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of NANOS1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NANOS1 mRNA

NCBI chr 1:259,897,663...259,901,561
Ensembl chr 1:259,897,939...259,898,730

G

nuclear autoantigenic sperm protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NASP mRNA

NCBI chr 5:130,057,363...130,083,003
Ensembl chr 5:130,057,363...130,082,928

G

neurobeachin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NBEA mRNA

NCBI chr 2:139,780,021...140,338,639
Ensembl chr 2:139,780,021...140,340,584

G

neurobeachin-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NBEAL1 mRNA

NCBI chr 9:61,575,154...61,743,896
Ensembl chr 9:61,575,356...61,736,750

G

non-SMC condensin I complex, subunit G

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NCAPG mRNA

NCBI chr14:65,403,930...65,432,902
Ensembl chr14:65,404,163...65,432,902

G

non-SMC condensin II complex, subunit G2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NCAPG2 mRNA

NCBI chr 6:137,342,449...137,418,083
Ensembl chr 6:137,342,943...137,415,159

G

nuclear receptor coactivator 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NCOA1 mRNA

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NCOA7 mRNA

NCBI chr 1:26,856,228...27,016,950
Ensembl chr 1:26,856,530...27,015,871

G

NDC1 transmembrane nucleoporin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDC1 mRNA

NCBI chr 5:122,155,992...122,202,295
Ensembl chr 5:122,155,967...122,202,291

G

NDC80 kinetochore complex component

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDC80 mRNA

NCBI chr 9:111,407,191...111,440,921
Ensembl chr 9:111,407,191...111,440,924

G

nudE neurodevelopment protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NDE1 mRNA

NCBI chr10:839,788...883,946
Ensembl chr10:839,788...883,869

G

Nedd4 family interacting protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NDFIP1 mRNA

NCBI chr18:30,265,808...30,316,068
Ensembl chr18:30,250,613...30,322,311

G

nebulette

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEBL mRNA

NCBI chr17:80,113,891...80,466,331
Ensembl chr17:80,118,543...80,466,210

G

NEDD4 like E3 ubiquitin protein ligase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEDD4L mRNA

NCBI chr18:58,393,759...58,726,709
Ensembl chr18:58,393,509...58,723,137

G

neural precursor cell expressed, developmentally down-regulated 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NEDD9 mRNA

NCBI chr17:23,289,793...23,468,026
Ensembl chr17:23,282,326...23,468,019

G

nei-like DNA glycosylase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NEIL3 mRNA

NCBI chr16:38,359,305...38,418,528
Ensembl chr16:38,359,371...38,418,527

G

neuralized E3 ubiquitin protein ligase 1B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NEURL1B mRNA

NCBI chr10:16,754,002...16,785,049
Ensembl chr10:16,757,208...16,785,119

G

nuclear factor of activated T-cells 2 interacting protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NFATC2IP mRNA

NCBI chr 1:180,954,834...180,971,847
Ensembl chr 1:180,955,043...180,971,747

G

nuclear factor, interleukin 3 regulated

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NFIL3 mRNA

NCBI chr17:12,280,499...12,295,728
Ensembl chr17:12,280,484...12,295,858

G

NHERF family PDZ scaffold protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NHERF1 mRNA

NCBI chr10:100,403,189...100,420,290
Ensembl chr10:100,403,069...100,420,598

G

ninein-like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NINL mRNA

NCBI chr 3:139,748,353...139,814,683
Ensembl chr 3:139,748,355...139,814,622

G

N-myristoyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NMT2 mRNA

NCBI chr17:74,917,833...74,964,788
Ensembl chr17:74,917,833...74,961,080

G

neuromedin U

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NMU mRNA

NCBI chr14:31,844,564...31,872,196
Ensembl chr14:31,844,728...31,872,192

G

nucleolar protein with MIF4G domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NOM1 mRNA

NCBI chr 4:5,891,220...5,910,741
Ensembl chr 4:5,892,909...5,909,709

G

neuronal PAS domain protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPAS3 mRNA

NCBI chr 6:70,702,773...71,527,928
Ensembl chr 6:70,703,170...71,524,884

G

aminopeptidase puromycin sensitive

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NPEPPS mRNA

NCBI chr10:82,191,454...82,273,967
Ensembl chr10:82,191,456...82,273,967

G

nephrocystin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPHP3 mRNA

NCBI chr 8:104,621,908...104,662,383
Ensembl chr 8:104,621,864...104,662,383

G

nephronectin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NPNT mRNA

NCBI chr 2:221,391,151...221,459,527
Ensembl chr 2:221,391,153...221,459,401

G

neuropeptide Y receptor Y1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NPY1R mRNA

NCBI chr16:23,037,788...23,047,330
Ensembl chr16:23,037,789...23,046,759

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NQO1 mRNA

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NQO2 mRNA

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 1, group I, member 2

increases activity

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 2, group F, member 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NR2F6 mRNA

NCBI chr16:18,046,012...18,053,914
Ensembl chr16:18,046,013...18,053,459

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NR4A2 mRNA

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

neuronal cell adhesion molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NRCAM mRNA

NCBI chr 6:61,402,813...61,698,536
Ensembl chr 6:61,329,863...61,702,992

G

nurim

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NRM mRNA

NCBI chr20:2,888,321...2,892,804
Ensembl chr20:2,877,567...2,891,802

G

nuclear receptor binding SET domain protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NSD2 mRNA

NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641

G

5' nucleotidase, ecto

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NT5E mRNA

NCBI chr 8:89,271,046...89,314,918
Ensembl chr 8:89,270,696...89,314,881

G

netrin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NTN4 mRNA

NCBI chr 7:28,186,611...28,300,390
Ensembl chr 7:28,186,611...28,300,390

G

NUAK family kinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of NUAK1 mRNA

NCBI chr 7:19,330,034...19,401,918
Ensembl chr 7:19,329,933...19,401,913

G

nudix hydrolase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUDT1 mRNA

NCBI chr12:14,302,514...14,309,559
Ensembl chr12:14,302,694...14,305,826

G

nucleoporin 107

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP107 mRNA

NCBI chr 7:53,353,740...53,398,345
Ensembl chr 7:53,353,743...53,398,370

G

nucleoporin 155

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP155 mRNA

NCBI chr 2:57,201,310...57,252,918
Ensembl chr 2:57,201,272...57,254,148

G

nucleoporin 210

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP210 mRNA

NCBI chr 4:123,511,558...123,609,874
Ensembl chr 4:123,511,559...123,609,874

G

nucleoporin 62 C-terminal like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUP62CL mRNA

NCBI chr X:103,668,458...103,724,957
Ensembl chr X:103,668,455...103,724,081

G

nucleolar and spindle associated protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of NUSAP1 mRNA

NCBI chr 3:106,603,273...106,633,428
Ensembl chr 3:106,603,289...106,633,624

G

ornithine decarboxylase antizyme 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OAZ2 mRNA

NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453

G

outer dense fiber of sperm tails 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ODF2 mRNA

NCBI chr 3:13,160,981...13,207,223
Ensembl chr 3:13,161,494...13,206,985

G

Opa interacting protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OIP5 mRNA

NCBI chr 3:106,593,746...106,603,281
Ensembl chr 3:106,593,760...106,603,250

G

olfactomedin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OLFM1 mRNA

NCBI chr 3:11,520,522...11,558,240
Ensembl chr 3:11,520,729...11,558,239

G

optineurin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OPTN mRNA

NCBI chr17:73,209,572...73,260,251
Ensembl chr17:73,209,575...73,260,251

G

origin recognition complex, subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ORC1 mRNA

NCBI chr 5:123,324,273...123,348,375
Ensembl chr 5:123,324,315...123,348,375

G

origin recognition complex, subunit 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ORC6 mRNA

NCBI chr19:21,757,867...21,765,638
Ensembl chr19:21,757,866...21,765,662

G

oxysterol binding protein-like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OSBPL2 mRNA

NCBI chr 3:167,210,945...167,256,219
Ensembl chr 3:167,210,832...167,256,219

G

oxidative stress responsive serine-rich 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OSER1 mRNA

NCBI chr 3:152,066,975...152,085,180
Ensembl chr 3:152,066,975...152,085,149

G

OTU deubiquitinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OTUD1 mRNA

NCBI chr17:82,259,920...82,262,770
Ensembl chr17:82,259,840...82,262,995

G

3-oxoacid CoA transferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of OXCT1 mRNA

NCBI chr 2:53,236,370...53,384,715
Ensembl chr 2:53,236,368...53,384,714

G

oxytocin receptor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of OXTR mRNA

NCBI chr 4:145,598,549...145,614,674
Ensembl chr 4:145,599,561...145,614,674

G

prolyl 4-hydroxylase subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of P4HB mRNA

NCBI chr10:105,836,972...105,848,583
Ensembl chr10:105,836,982...105,848,500

G

phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PAICS mRNA

NCBI chr14:31,199,086...31,232,731
Ensembl chr14:31,173,541...31,232,635

G

3'-phosphoadenosine 5'-phosphosulfate synthase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PAPSS2 mRNA

NCBI chr 1:230,454,314...230,539,332
Ensembl chr 1:230,454,426...230,539,331

G

poly (ADP-ribose) polymerase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

poly (ADP-ribose) polymerase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARP2 mRNA

NCBI chr15:24,034,069...24,044,340
Ensembl chr15:24,034,106...24,044,338

G

PARP1 binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PARPBP mRNA

NCBI chr 7:22,511,427...22,580,834
Ensembl chr 7:22,511,427...22,573,695

G

parvin, alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PARVA mRNA

NCBI chr 1:166,547,142...166,704,958
Ensembl chr 1:166,547,132...166,704,950

G

pro-apoptotic WT1 regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PAWR mRNA

NCBI chr 7:43,645,028...43,725,033
Ensembl chr 7:43,645,084...43,725,028

G

PDZ binding kinase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PBK mRNA

NCBI chr15:40,022,873...40,034,014
Ensembl chr15:40,023,002...40,034,014

G

phosphoenolpyruvate carboxykinase 2 (mitochondrial)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCK2 mRNA

NCBI chr15:29,027,891...29,036,729
Ensembl chr15:29,027,894...29,037,283

G

PCNA clamp associated factor

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCLAF mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of PCLAF mRNA

NCBI chr 8:66,420,606...66,432,994
Ensembl chr 8:66,420,587...66,432,994
Ensembl chr 8:66,420,587...66,432,994

G

protein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCMTD1 mRNA

NCBI chr 5:12,284,711...12,355,680
Ensembl chr 5:12,284,711...12,354,899

G

proliferating cell nuclear antigen

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCNA mRNA

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

pericentrin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PCNT mRNA

NCBI chr20:12,190,597...12,278,723
Ensembl chr20:12,191,648...12,278,710

G

proprotein convertase subtilisin/kexin type 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PCSK6 mRNA

NCBI chr 1:119,428,978...119,627,626
Ensembl chr 1:119,429,265...119,627,596

G

programmed cell death 4

increases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of PDCD4 mRNA

NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275

G

programmed cell death 6 interacting protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PDCD6IP mRNA

NCBI chr 8:113,590,998...113,646,795
Ensembl chr 8:113,590,998...113,646,773

G

protein disulfide isomerase family A, member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDIA3 mRNA

NCBI chr 3:108,388,189...108,412,013
Ensembl chr 3:108,388,245...108,413,236

G

protein disulfide isomerase family A, member 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDIA6 mRNA

NCBI chr 6:40,062,980...40,080,223
Ensembl chr 6:40,062,926...40,080,613

G

PDZ and LIM domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PDLIM1 mRNA

NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:239,042,385...239,091,076

G

PDZ domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PDZK1 mRNA

NCBI chr 2:184,376,161...184,407,514
Ensembl chr 2:184,376,161...184,407,514

G

phosphofructokinase, liver type

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PFKL mRNA

NCBI chr20:10,664,285...10,686,324
Ensembl chr20:10,664,272...10,686,315

G

protein geranylgeranyltransferase type I subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGGT1B mRNA

NCBI chr18:38,952,147...38,995,656
Ensembl chr18:38,952,914...38,995,503

G

phosphoglucomutase 2-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGM2L1 mRNA

NCBI chr 1:154,571,410...154,620,901
Ensembl chr 1:154,571,766...154,620,902

G

phosphoglucomutase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGM3 mRNA

NCBI chr 8:87,518,317...87,536,021
Ensembl chr 8:87,517,701...87,536,022

G

progesterone receptor membrane component 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PGRMC1 mRNA

NCBI chr X:115,832,865...115,841,060
Ensembl chr X:115,832,884...115,888,682

G

progesterone receptor membrane component 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PGRMC2 mRNA

NCBI chr 2:124,068,257...124,084,155
Ensembl chr 2:124,068,260...124,084,155

G

phosphatase and actin regulator 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHACTR2 mRNA

NCBI chr 1:7,591,254...7,860,431
Ensembl chr 1:7,597,927...7,860,289

G

PHD finger protein 19

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PHF19 mRNA

NCBI chr 3:18,175,281...18,197,289
Ensembl chr 3:18,175,282...18,196,405

G

PHD finger protein 20-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHF20L1 mRNA

NCBI chr 7:98,330,580...98,396,526
Ensembl chr 7:98,330,580...98,396,526

G

pleckstrin homology-like domain, family A, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHLDA2 mRNA

NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:198,696,897...198,697,836

G

pleckstrin homology-like domain, family B, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PHLDB2 mRNA

NCBI chr11:54,859,173...55,078,212
Ensembl chr11:54,859,135...55,078,467

G

phosphatidylinositol 3-kinase, catalytic subunit type 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PIK3C3 mRNA

NCBI chr18:21,845,282...21,934,387
Ensembl chr18:21,845,295...21,929,048

G

PICALM interacting mitotic regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PIMREG mRNA

NCBI chr10:56,669,603...56,674,540
Ensembl chr10:56,669,675...56,674,791

G

cAMP-dependent protein kinase inhibitor beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKIB mRNA

NCBI chr20:36,965,172...37,062,190
Ensembl chr20:36,905,340...37,062,187

G

pyruvate kinase M1/2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKM mRNA

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

protein kinase, membrane associated tyrosine/threonine 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PKMYT1 mRNA

NCBI chr10:12,748,221...12,758,995
Ensembl chr10:12,748,237...12,758,995

G

phosphatidylinositol-specific phospholipase C, X domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLCXD1 mRNA

NCBI chr12:46,578,917...46,582,181
Ensembl chr12:46,579,225...46,582,392

G

pleckstrin homology domain containing A5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PLEKHA5 mRNA

NCBI chr 4:173,333,891...173,503,546
Ensembl chr 4:173,334,055...173,503,546

G

pleckstrin homology domain containing B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PLEKHB2 mRNA

NCBI chr 9:37,049,580...37,082,231
Ensembl chr 9:37,038,751...37,082,231

G

polo-like kinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLK1 mRNA

NCBI chr 1:176,716,420...176,726,400
Ensembl chr 1:176,716,420...176,726,400

G

polo-like kinase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLK4 mRNA

NCBI chr 2:123,802,527...123,820,942
Ensembl chr 2:123,802,512...123,820,942

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PLOD2 mRNA

NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255

G

prostate transmembrane protein, androgen induced 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PMEPA1 mRNA

NCBI chr 3:162,011,884...162,060,343
Ensembl chr 3:162,012,751...162,060,454

G

peptidase, mitochondrial processing subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PMPCB mRNA

NCBI chr 4:13,297,583...13,310,363
Ensembl chr 4:13,297,559...13,310,367

G

purine nucleoside phosphorylase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PNP mRNA

NCBI chr15:24,170,607...24,178,269
Ensembl chr15:24,170,602...24,203,986

G

DNA polymerase alpha 1, catalytic subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLA1 mRNA

NCBI chr X:58,034,617...58,348,612
Ensembl chr X:58,034,619...58,348,536

G

DNA polymerase alpha 2, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLA2 mRNA

NCBI chr 1:203,227,183...203,251,350
Ensembl chr 1:203,203,388...203,251,348

G

DNA polymerase delta 1, catalytic subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD1 mRNA

NCBI chr 1:95,025,462...95,041,559
Ensembl chr 1:95,025,499...95,036,465

G

DNA polymerase delta 2, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD2 mRNA

NCBI chr14:80,748,971...80,755,188
Ensembl chr14:80,748,974...80,755,160

G

DNA polymerase delta 3, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLD3 mRNA

NCBI chr 1:154,417,893...154,456,687
Ensembl chr 1:154,418,084...154,456,665

G

DNA polymerase epsilon, catalytic subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE mRNA

NCBI chr12:46,345,420...46,393,984
Ensembl chr12:46,345,420...46,393,939

G

DNA polymerase epsilon 2, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE2 mRNA

NCBI chr 6:87,674,702...87,712,723
Ensembl chr 6:87,674,702...87,699,305

G

DNA polymerase epsilon 3, accessory subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of POLE3 mRNA

NCBI chr 5:75,973,941...75,977,175
Ensembl chr 5:75,974,717...75,977,231
Ensembl chr 7:75,974,717...75,977,231

G

phosphoribosyl pyrophosphate amidotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPAT mRNA

NCBI chr14:31,215,741...31,250,144
Ensembl chr14:31,216,165...31,250,144

G

peptidylprolyl isomerase F

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPIF mRNA

NCBI chr16:1,257,197...1,263,919
Ensembl chr16:1,257,106...1,263,913

G

periplakin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPL mRNA

NCBI chr10:10,450,919...10,496,575
Ensembl chr10:10,450,919...10,496,575

G

protein phosphatase 1, regulatory subunit 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PPP1R10 mRNA

NCBI chr20:2,822,995...2,838,125
Ensembl chr20:2,822,995...2,837,611

G

protein phosphatase 2, regulatory subunit B, alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP2R2A mRNA

NCBI chr15:41,204,659...41,263,924
Ensembl chr15:41,204,200...41,263,924

G

protein phosphatase 2, regulatory subunit B'', alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP2R3A mRNA

NCBI chr 8:101,703,512...101,841,530
Ensembl chr 8:101,704,778...101,841,502

G

protein phosphatase 3 catalytic subunit gamma

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PPP3CC mRNA

NCBI chr15:45,289,917...45,362,012
Ensembl chr15:45,290,373...45,361,832

G

peroxiredoxin 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRDX4 mRNA

NCBI chr X:40,026,762...40,044,066
Ensembl chr X:40,026,651...40,044,066

G

phosphatidylinositol-3,4,5-trisphosphate-dependent Rac exchange factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PREX1 mRNA

NCBI chr 3:155,306,950...155,456,688
Ensembl chr 3:155,306,950...155,456,688

G

DNA primase subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRIM1 mRNA

NCBI chr 7:446,342...462,526
Ensembl chr 7:431,805...462,526

G

DNA primase subunit 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRIM2 mRNA

NCBI chr 9:35,692,376...35,904,521
Ensembl chr 9:35,692,376...35,903,030

G

protein kinase, DNA-activated, catalytic subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRKDC mRNA

NCBI chr11:85,040,790...85,258,357
Ensembl chr11:85,040,792...85,257,952

G

pre-mRNA splicing tri-snRNP complex factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRPF4 mRNA

NCBI chr 5:75,859,934...75,873,924
Ensembl chr 5:75,859,924...75,873,919

G

proline rich 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRR14 mRNA

NCBI chr 1:182,083,838...182,089,330
Ensembl chr 1:182,084,126...182,089,317

G

proline-rich coiled-coil 2A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PRRC2A mRNA

NCBI chr20:3,658,391...3,674,143
Ensembl chr20:3,658,695...3,674,130

G

proline-rich coiled-coil 2C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRRC2C mRNA

NCBI chr13:75,003,995...75,073,701
Ensembl chr13:75,004,010...75,073,643

G

proline-rich transmembrane protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRRT3 mRNA

NCBI chr 4:146,641,173...146,650,487
Ensembl chr 4:146,641,173...146,650,317

G

serine protease 23

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PRSS23 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of PRSS23 mRNA

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:143,401,396...143,422,091

G

PC4 and SRSF1 interacting protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSIP1 mRNA

NCBI chr 5:97,847,010...97,879,280
Ensembl chr 5:97,847,015...97,879,257

G

proteasome 26S subunit, ATPase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSMC3 mRNA

NCBI chr 3:77,031,825...77,037,207
Ensembl chr 3:77,031,825...77,043,358

G

proline and serine rich coiled-coil 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PSRC1 mRNA

NCBI chr 2:196,022,361...196,026,874
Ensembl chr 2:196,022,361...196,026,874

G

polypyrimidine tract binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTBP1 mRNA

NCBI chr 7:9,842,574...9,852,332
Ensembl chr 7:9,842,574...9,852,397

G

prostaglandin E synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTGES mRNA

NCBI chr 3:14,177,892...14,189,236

G

protein tyrosine phosphatase 4A1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTP4A1 mRNA

NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964

G

protein tyrosine phosphatase, non-receptor type 12

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PTPN12 mRNA

NCBI chr 4:14,020,997...14,092,931
Ensembl chr 4:14,021,052...14,092,927

G

protein tyrosine phosphatase, non-receptor type 21

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PTPN21 mRNA

NCBI chr 6:117,933,066...117,998,095
Ensembl chr 6:117,933,066...117,998,095

G

PTTG1 regulator of sister chromatid separation, securin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of PTTG1 mRNA

NCBI chr10:27,893,466...27,904,965
Ensembl chr10:27,893,689...27,904,837

G

pseudouridine synthase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PUS3 mRNA

NCBI chr 8:33,910,461...33,918,716
Ensembl chr 8:33,911,357...33,918,714

G

pyridine nucleotide-disulphide oxidoreductase domain 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of PYROXD1 mRNA

NCBI chr 4:175,292,124...175,311,143
Ensembl chr 4:175,292,177...175,308,689

G

glutamine and serine rich 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of QSER1 mRNA

NCBI chr 3:91,137,516...91,202,426
Ensembl chr 3:91,140,967...91,202,052

G

RAB2A, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB2 mRNA

NCBI chr 5:21,676,017...21,740,035
Ensembl chr 5:21,676,129...21,739,899

G

RAB31, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAB31 mRNA

NCBI chr 9:105,246,712...105,382,973
Ensembl chr 9:105,246,709...105,381,253

G

RAB32, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB32 mRNA

NCBI chr 1:4,946,193...4,961,003
Ensembl chr 1:4,945,036...4,960,934

G

Rab40b, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAB40B mRNA

NCBI chr10:106,631,514...106,659,090
Ensembl chr10:106,631,514...106,659,090

G

RAB8A, member RAS oncogene family

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAB8A mRNA

NCBI chr16:17,654,027...17,675,385
Ensembl chr16:17,654,034...17,675,678

G

Rac GTPase-activating protein 1

increases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of RACGAP1 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RACGAP1 mRNA

NCBI chr 7:130,750,936...130,780,891
Ensembl chr 7:130,750,936...130,780,831

G

RAD21 cohesin complex component

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD21 mRNA

NCBI chr 7:83,287,867...83,314,810
Ensembl chr 7:83,287,870...83,314,817

G

RAD51 recombinase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51 mRNA

NCBI chr 3:106,099,753...106,125,038
Ensembl chr 3:106,100,381...106,125,035

G

RAD51 associated protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51AP1 mRNA

NCBI chr 4:159,759,454...159,772,473
Ensembl chr 4:159,759,459...159,772,524

G

RAD51 paralog C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD51C mRNA

NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,205,032...72,231,248

G

RAD54 homolog B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD54B mRNA

NCBI chr 5:25,032,112...25,104,630
Ensembl chr 5:25,032,066...25,104,616

G

RAD54 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAD54L mRNA

NCBI chr 5:129,575,431...129,605,100
Ensembl chr 5:129,575,378...129,605,070

G

RAN binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RANBP1 mRNA

NCBI chr11:82,742,603...82,750,836
Ensembl chr11:82,742,600...82,750,838

G

RAN GTPase activating protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RANGAP1 mRNA

NCBI chr 7:113,224,695...113,250,441
Ensembl chr 7:113,224,703...113,250,438

G

Rap guanine nucleotide exchange factor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RAPGEF2 mRNA

NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247

G

Rap guanine nucleotide exchange factor like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAPGEFL1 mRNA

NCBI chr10:83,793,711...83,810,373
Ensembl chr10:83,793,694...83,810,371

G

ras related dexamethasone induced 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASD1 mRNA

NCBI chr10:44,766,451...44,775,773
Ensembl chr10:44,766,455...44,768,186

G

RAS and EF hand domain containing

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASEF mRNA

NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:87,548,908...87,619,031

G

RAS-like family 11 member B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASL11B mRNA

NCBI chr14:34,014,924...34,019,146
Ensembl chr14:34,014,509...34,019,152

G

Ras association domain family member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RASSF3 mRNA

NCBI chr 7:56,935,888...57,000,554
Ensembl chr 7:56,935,973...57,000,553

G

ribonucleoprotein, PTB-binding 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RAVER1 mRNA

NCBI chr 8:19,610,464...19,629,188
Ensembl chr 8:19,610,466...19,629,152

G

RB1-inducible coiled-coil 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RB1CC1 mRNA

NCBI chr 5:13,161,648...13,225,560
Ensembl chr 5:13,161,648...13,225,560

G

RB binding protein 4, chromatin remodeling factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP4 mRNA

NCBI chr 5:141,655,863...141,675,157
Ensembl chr 5:141,638,421...141,675,284

G

RB binding protein 8, endonuclease

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP8 mRNA

NCBI chr18:2,922,985...2,988,851
Ensembl chr18:2,921,286...2,988,846

G

RB binding protein 9, serine hydrolase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBBP9 mRNA

NCBI chr 3:131,925,095...131,939,042
Ensembl chr 3:131,925,341...131,932,156

G

RNA binding fox-1 homolog 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RBFOX2 mRNA

NCBI chr 7:108,810,627...109,054,420
Ensembl chr 7:108,810,628...109,054,691

G

RNA binding motif protein 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBM10 mRNA

NCBI chr X:1,540,399...1,572,571
Ensembl chr X:1,540,398...1,572,575

G

RNA binding motif protein 15

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RBM15 mRNA

NCBI chr 2:194,945,974...194,954,498
Ensembl chr 2:194,945,974...194,954,703

G

RNA binding motif, single stranded interacting protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RBMS1 mRNA

NCBI chr 3:45,195,828...45,420,406
Ensembl chr 3:45,197,972...45,420,376

G

regulator of calcineurin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RCAN1 mRNA

NCBI chr11:31,622,208...31,702,150
Ensembl chr11:31,622,210...31,702,045

G

RCC1 domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RCCD1 mRNA

NCBI chr 1:134,271,870...134,281,556
Ensembl chr 1:134,271,857...134,280,781

G

REST corepressor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RCOR3 mRNA

NCBI chr13:103,624,966...103,665,565
Ensembl chr13:103,624,971...103,665,565

G

RAD52 motif containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RDM1 mRNA

NCBI chr10:86,562,871...86,573,034
Ensembl chr10:86,539,553...86,573,034

G

RecQ like helicase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RECQL4 mRNA

NCBI chr 7:108,423,453...108,430,790
Ensembl chr 7:108,423,455...108,430,619

G

receptor accessory protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of REEP3 mRNA

NCBI chr20:21,493,868...21,578,698
Ensembl chr20:21,493,954...21,578,697

G

receptor accessory protein 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of REEP5 mRNA

NCBI chr18:25,945,375...25,983,271
Ensembl chr18:25,945,381...25,976,509

G

RAS-like, estrogen-regulated, growth-inhibitor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RERG mRNA

NCBI chr 4:169,981,634...170,089,777
Ensembl chr 4:169,982,279...170,089,715

G

ret proto-oncogene

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RET mRNA

NCBI chr 4:151,325,969...151,368,176
Ensembl chr 4:151,326,431...151,368,176

G

replication factor C subunit 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC2 mRNA

NCBI chr12:22,120,449...22,133,576
Ensembl chr12:22,120,010...22,133,557

G

replication factor C subunit 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC3 mRNA

NCBI chr12:1,000,987...1,011,778
Ensembl chr12:1,000,994...1,011,778

G

replication factor C subunit 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC4 mRNA

NCBI chr11:77,749,642...77,764,123
Ensembl chr11:77,749,638...77,764,122

G

replication factor C subunit 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RFC5 mRNA

NCBI chr12:39,207,484...39,217,041
Ensembl chr12:39,207,484...39,217,312

G

raftlin lipid raft linker 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RFTN1 mRNA

NCBI chr 9:10,804,611...11,002,084
Ensembl chr 9:10,804,611...11,002,084

G

regulator of G-protein signaling 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RGS2 mRNA

NCBI chr13:55,799,749...55,802,354
Ensembl chr13:55,798,829...55,802,385

G

rhomboid 5 homolog 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHBDF1 mRNA

NCBI chr10:15,406,832...15,419,765
Ensembl chr10:15,406,859...15,419,763

G

RAD9-HUS1-RAD1 interacting nuclear orphan 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RHNO1 mRNA

NCBI chr 4:161,634,047...161,639,437
Ensembl chr 4:161,634,048...161,639,371

G

ras homolog family member Q

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHOQ mRNA

NCBI chr 6:7,613,632...7,652,047

G

ras homolog family member T1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RHOT1 mRNA

NCBI chr10:65,198,700...65,262,807
Ensembl chr10:65,170,560...65,262,804

G

regulator of microtubule dynamics 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RMDN2 mRNA

NCBI chr 6:15,372,569...15,443,000
Ensembl chr 6:15,375,496...15,441,480

G

RecQ mediated genome instability 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RMI1 mRNA

NCBI chr17:6,256,533...6,264,523
Ensembl chr17:6,256,450...6,264,695

G

RecQ mediated genome instability 2

increases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of RMI2 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RMI2 mRNA

NCBI chr10:4,829,333...4,837,264
Ensembl chr10:4,830,553...4,837,235

G

ribonuclease H2, subunit A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNASEH2A mRNA

NCBI chr19:23,186,325...23,196,045
Ensembl chr19:23,186,383...23,196,041

G

ring finger protein 187

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNF187 mRNA

NCBI chr10:43,709,493...43,715,392
Ensembl chr10:43,702,357...43,716,157

G

ring finger protein 19A, RBR E3 ubiquitin protein ligase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RNF19A mRNA

NCBI chr 7:67,425,833...67,465,214
Ensembl chr 7:67,425,837...67,465,222

G

ring finger protein 26

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RNF26 mRNA

NCBI chr 8:44,454,551...44,456,745
Ensembl chr 8:44,454,292...44,457,331

G

Rho-associated coiled-coil containing protein kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ROCK2 mRNA

NCBI chr 6:39,679,116...39,774,033
Ensembl chr 6:39,679,082...39,774,031

G

replication protein A1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPA1 mRNA

NCBI chr10:60,148,869...60,199,970
Ensembl chr10:60,148,793...60,199,949

G

replication protein A3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPA3 mRNA

NCBI chr 4:36,304,649...36,307,755
Ensembl chr 4:36,304,651...36,307,709

G

ribosomal protein L39 like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RPL39L mRNA

NCBI chr10:5,455,712...5,459,828
Ensembl chr10:5,454,559...5,462,029

G

Ras-related GTP binding C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RRAGC mRNA

NCBI chr 5:136,148,239...136,167,773
Ensembl chr 5:136,148,276...136,167,767

G

ribonucleotide reductase catalytic subunit M1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RRM1 mRNA

NCBI chr 1:156,823,960...156,848,262
Ensembl chr 1:156,823,960...156,848,261

G

ribonucleotide reductase regulatory subunit M2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RRM2 mRNA

NCBI chr 6:41,339,858...41,346,774
Ensembl chr 6:41,340,557...41,346,773

G

arginine and serine rich coiled-coil 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of RSRC1 mRNA

NCBI chr 2:151,226,821...151,632,771
Ensembl chr 2:151,231,156...151,632,765

G

Ras suppressor protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RSU1 mRNA

NCBI chr17:76,128,774...76,377,515
Ensembl chr17:76,188,812...76,377,454

G

RUN domain containing 3B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of RUNDC3B mRNA

NCBI chr 4:25,462,543...25,599,477
Ensembl chr 4:25,462,752...25,599,471

G

S100 calcium binding protein A10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of S100A10 mRNA

NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661

G

sphingosine-1-phosphate receptor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of S1PR3 mRNA

NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,781,050...13,794,505

G

SUMO1 activating enzyme subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SAE1 mRNA

NCBI chr 1:77,030,961...77,086,937
Ensembl chr 1:77,030,965...77,086,986

G

spalt-like transcription factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SALL4 mRNA

NCBI chr 3:157,474,067...157,491,055
Ensembl chr 3:157,474,642...157,490,822

G

SAM and SH3 domain containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SASH1 mRNA

NCBI chr 1:3,119,915...3,418,536
Ensembl chr 1:3,121,332...3,439,870

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SAT1 mRNA

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:40,157,046...40,196,813

G

scavenger receptor class B, member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SCARB1 mRNA

NCBI chr12:31,296,143...31,362,649
Ensembl chr12:31,296,156...31,362,647

G

scavenger receptor class B, member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SCARB2 mRNA

NCBI chr14:15,558,271...15,609,813
Ensembl chr14:15,558,236...15,609,813

G

saccharopine dehydrogenase (putative)

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SCCPDH mRNA

NCBI chr13:91,400,120...91,421,875
Ensembl chr13:91,400,190...91,422,222

G

selectin E

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of SELE protein

NCBI chr13:76,402,841...76,412,741
Ensembl chr13:76,403,304...76,412,741

G

selenoprotein P

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SELENOP mRNA

NCBI chr 2:52,498,123...52,508,409
Ensembl chr 2:52,498,339...52,508,852

G

selenophosphate synthetase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SEPHS1 mRNA

NCBI chr17:73,354,435...73,382,803
Ensembl chr17:73,356,530...73,382,593

G

serine incorporator 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SERINC5 mRNA

NCBI chr 2:23,846,899...23,950,346
Ensembl chr 2:23,846,900...23,950,346

G

splicing factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SF1 mRNA

NCBI chr 1:203,670,016...203,683,432
Ensembl chr 1:203,670,018...203,684,330

G

splicing factor 3b, subunit 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SF3B3 mRNA

NCBI chr19:38,782,749...38,820,271
Ensembl chr19:38,783,040...38,820,245

G

stratifin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

sideroflexin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SFXN2 mRNA

NCBI chr 1:245,447,014...245,459,312
Ensembl chr 1:245,447,015...245,468,411
Ensembl chr 1:245,447,015...245,468,411

G

sarcoglycan, gamma

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SGCG mRNA

NCBI chr15:35,388,836...35,435,072
Ensembl chr15:35,386,534...35,435,148

G

serum/glucocorticoid regulated kinase family, member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGK3 mRNA

NCBI chr 5:9,345,761...9,472,243
Ensembl chr 5:9,346,040...9,415,476

G

shugoshin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO1 mRNA

NCBI chr 9:6,672,109...6,687,908
Ensembl chr 9:6,672,123...6,687,805

G

shugoshin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SGO2 mRNA

NCBI chr 9:59,548,605...59,573,229
Ensembl chr 9:59,548,683...59,573,229

G

SH3 domain binding glutamate rich protein like 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3BGRL mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of SH3BGRL mRNA

NCBI chr X:74,167,029...74,263,783
Ensembl chr X:74,166,871...74,263,783

G

SH3-domain binding protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3BP4 mRNA

NCBI chr 9:89,660,156...89,739,163
Ensembl chr 9:89,660,156...89,739,163

G

SH3 domain-containing kinase-binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SH3KBP1 mRNA

NCBI chr X:34,877,862...35,223,013
Ensembl chr X:34,877,866...35,222,747

G

SHC binding and spindle associated 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHCBP1 mRNA

NCBI chr16:84,672,277...84,703,843
Ensembl chr16:84,672,321...84,703,844

G

shisa family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SHISA2 mRNA

NCBI chr15:33,806,715...33,811,013
Ensembl chr15:33,805,958...33,811,013

G

serine hydroxymethyltransferase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHMT1 mRNA

NCBI chr10:45,468,698...45,490,833
Ensembl chr10:45,468,700...45,497,820

G

serine hydroxymethyltransferase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SHMT2 mRNA

NCBI chr 7:63,358,961...63,364,293
Ensembl chr 7:63,358,961...63,364,236

G

spindle and kinetochore associated complex subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA1 mRNA

NCBI chr18:67,794,722...67,805,037
Ensembl chr18:67,794,725...67,805,037

G

spindle and kinetochore associated complex subunit 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA2 mRNA

NCBI chr10:71,921,474...71,939,461
Ensembl chr10:71,921,582...71,939,458

G

spindle and kinetochore associated complex subunit 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKA3 mRNA

NCBI chr15:31,951,812...31,971,010
Ensembl chr15:31,951,825...31,971,010

G

S-phase kinase associated protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SKP2 mRNA

NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338

G

stem-loop histone mRNA binding protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLBP mRNA

NCBI chr14:77,071,441...77,081,911
Ensembl chr14:77,071,632...77,081,906

G

solute carrier family 12 member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC12A2 mRNA

NCBI chr18:51,348,282...51,416,448
Ensembl chr18:51,348,302...51,416,440

G

solute carrier family 12 member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC12A4 mRNA

NCBI chr19:33,838,418...33,860,369
Ensembl chr19:33,838,419...33,860,331

G

solute carrier family 12, member 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC12A8 mRNA

NCBI chr11:67,116,876...67,266,548
Ensembl chr11:67,116,877...67,266,834

G

solute carrier family 1 member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC1A4 mRNA

NCBI chr14:94,530,801...94,560,190
Ensembl chr14:94,529,084...94,560,418

G

solute carrier family 25 member 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC25A11 mRNA

NCBI chr10:55,357,590...55,360,441
Ensembl chr10:55,357,597...55,360,410

G

solute carrier family 25, member 39

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC25A39 mRNA

NCBI chr10:87,362,494...87,367,358
Ensembl chr10:87,362,490...87,367,260

G

solute carrier family 26 member 11

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC26A11 mRNA

NCBI chr10:104,613,498...104,635,873
Ensembl chr10:104,613,564...104,635,970

G

solute carrier family 27 member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC27A2 mRNA

NCBI chr 3:113,804,728...113,842,208
Ensembl chr 3:113,804,728...113,842,208

G

solute carrier family 27 member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC27A3 mRNA

NCBI chr 2:175,853,241...175,857,909
Ensembl chr 2:175,853,241...175,857,909

G

solute carrier family 29 member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC29A1 mRNA

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

SLC2A4 regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC2A4RG mRNA

NCBI chr 3:168,493,975...168,497,616

G

solute carrier family 35 member D2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC35D2 mRNA

NCBI chr17:987,899...1,019,747
Ensembl chr17:988,157...1,019,743

G

solute carrier family 37 member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC37A4 mRNA

NCBI chr 8:44,723,216...44,729,301
Ensembl chr 8:44,723,339...44,729,301

G

solute carrier family 39 member 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC39A8 mRNA

NCBI chr 2:224,171,787...224,319,326
Ensembl chr 2:224,256,654...224,319,129

G

solute carrier family 6 member 14

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC6A14 mRNA

NCBI chr X:112,314,643...112,375,412
Ensembl chr X:112,314,691...112,375,096

G

solute carrier family 7 member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC7A1 mRNA

NCBI chr12:6,628,288...6,703,849
Ensembl chr12:6,628,007...6,703,849

G

solute carrier family 7 member 11

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of SLC7A11 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

SMC5-SMC6 complex localization factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SLF1 mRNA

NCBI chr 2:6,767,015...6,874,428
Ensembl chr 2:6,767,015...6,867,149

G

SMAD family member 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD2 mRNA

NCBI chr18:69,849,884...69,918,926
Ensembl chr18:69,850,377...69,912,323

G

SMAD family member 3

decreases expression
multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of SMAD3 mRNA
[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMAD3 mRNA

NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960

G

structural maintenance of chromosomes 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC1A mRNA

NCBI chr X:21,103,323...21,148,053
Ensembl chr X:21,103,282...21,148,056

G

structural maintenance of chromosomes 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC2 mRNA

NCBI chr 5:66,806,882...66,853,478
Ensembl chr 5:66,807,011...66,853,242

G

structural maintenance of chromosomes 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SMC4 mRNA

NCBI chr 2:153,240,243...153,268,722
Ensembl chr 2:153,240,283...153,271,571

G

SET and MYND domain containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SMYD2 mRNA

NCBI chr13:101,425,270...101,466,576
Ensembl chr13:101,425,273...101,466,576

G

stannin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNN mRNA

NCBI chr10:4,572,933...4,581,606
Ensembl chr10:4,572,376...4,584,021

G

small nucleolar RNA, H/ACA box 24

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNORA24 mRNA

NCBI chr 2:82,490,770...82,490,892
Ensembl chr 2:82,490,770...82,490,892
Ensembl chr 2:82,490,770...82,490,892

G

small nucleolar RNA, C/D box 52

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNORD52 mRNA

NCBI chr20:3,878,412...3,878,477
Ensembl chr20:3,878,412...3,878,477

G

small nuclear ribonucleoprotein U11/U12 subunit 25

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRNP25 mRNA

NCBI chr10:15,420,482...15,423,806
Ensembl chr10:15,420,486...15,423,804

G

small nuclear ribonucleoprotein polypeptide A'

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRPA1 mRNA

NCBI chr 1:119,641,402...119,654,653
Ensembl chr 1:119,638,481...119,654,653

G

small nuclear ribonucleoprotein polypeptides B and B1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNRPB mRNA

NCBI chr 3:117,369,816...117,379,344
Ensembl chr 3:117,370,100...117,379,339

G

sorting nexin 10

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNX10 mRNA

NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:80,612,669...80,676,996

G

sorting nexin 24

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SNX24 mRNA

NCBI chr18:46,670,987...46,826,070
Ensembl chr18:46,671,443...46,826,068

G

sorting nexin 29

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX29 mRNA

NCBI chr10:3,884,880...4,298,699
Ensembl chr10:3,888,301...4,298,655

G

sorting nexin 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX6 mRNA

NCBI chr 6:72,230,950...72,274,157
Ensembl chr 6:72,229,870...72,315,911

G

sorting nexin 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SNX9 mRNA

NCBI chr 1:46,424,897...46,510,096
Ensembl chr 1:46,423,553...46,509,036

G

suppressor of cytokine signaling 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOCS2 mRNA

NCBI chr 7:30,006,360...30,045,161
Ensembl chr 7:30,008,578...30,043,548

G

SRY-box transcription factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SOX3 mRNA

NCBI chr X:139,308,608...139,310,687
Ensembl chr X:139,309,329...139,310,678

G

SRY-box transcription factor 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOX4 mRNA

NCBI chr17:35,667,809...35,672,515
Ensembl chr17:35,667,537...35,673,665

G

SRY-box transcription factor 9

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

sperm associated antigen 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPAG5 mRNA

NCBI chr10:63,198,717...63,216,746
Ensembl chr10:63,198,768...63,216,745

G

spermatogenesis associated 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SPATA7 mRNA

NCBI chr 6:117,879,828...117,925,284
Ensembl chr 6:117,879,823...117,925,284

G

SPC24 component of NDC80 kinetochore complex

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPC24 mRNA

NCBI chr 8:20,300,315...20,305,354
Ensembl chr 8:20,300,319...20,305,310

G

SPC25 component of NDC80 kinetochore complex

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPC25 mRNA

NCBI chr 3:53,930,013...53,988,940
Ensembl chr 3:53,975,704...53,988,959

G

spindle apparatus coiled-coil protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPDL1 mRNA

NCBI chr10:19,269,125...19,294,213
Ensembl chr10:19,269,127...19,294,127

G

spindlin family, member 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SPIN4 mRNA

NCBI chr X:59,888,728...59,892,817
Ensembl chr X:59,891,581...59,892,330

G

sprouty-related, EVH1 domain containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SPRED2 mRNA

NCBI chr14:94,149,210...94,250,787
Ensembl chr14:94,148,837...94,249,162

G

sulfide quinone oxidoreductase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SQOR mRNA

NCBI chr 3:109,841,225...109,886,724
Ensembl chr 3:109,841,250...109,960,778

G

sequestosome 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SQSTM1 mRNA

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

steroid 5 alpha-reductase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRD5A3 mRNA

NCBI chr14:32,046,408...32,060,796
Ensembl chr14:32,046,408...32,060,747

G

sorcin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SRI mRNA

NCBI chr 4:25,973,493...25,997,879
Ensembl chr 4:25,966,750...25,998,077

G

spermidine synthase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRM mRNA

NCBI chr 5:159,025,875...159,029,076
Ensembl chr 5:159,025,873...159,029,405

G

SRP receptor subunit beta

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRPRB mRNA

NCBI chr 8:103,768,685...103,782,632

G

serrate, RNA effector molecule

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRRT mRNA

NCBI chr12:19,392,578...19,406,098
Ensembl chr12:19,392,625...19,406,095

G

serine and arginine rich splicing factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SRSF1 mRNA

NCBI chr10:72,838,926...72,859,066
Ensembl chr10:72,839,274...72,845,336

G

single-stranded DNA binding protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SSBP2 mRNA

NCBI chr 2:22,650,488...22,938,669
Ensembl chr 2:22,651,258...22,933,696

G

structure specific recognition protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SSRP1 mRNA

NCBI chr 3:70,124,371...70,134,481
Ensembl chr 3:70,118,655...70,134,482

G

ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ST8SIA4 mRNA

NCBI chr 9:95,990,131...96,084,661
Ensembl chr 9:95,993,503...96,084,653

G

STIL, centriolar assembly protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of STIL mRNA

NCBI chr 5:128,520,837...128,573,732
Ensembl chr 5:128,520,953...128,573,730

G

serine/threonine kinase 38 like

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STK38L mRNA

NCBI chr 4:179,616,288...179,693,177
Ensembl chr 4:179,634,275...179,690,983

G

stathmin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of STMN1 mRNA

NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154

G

stonin 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STON2 mRNA

NCBI chr 6:110,567,485...110,676,376
Ensembl chr 6:110,567,485...110,676,376

G

striatin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STRN3 mRNA

NCBI chr 6:69,047,776...69,134,102
Ensembl chr 6:69,047,776...69,134,102

G

syntaxin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STX3 mRNA

NCBI chr 1:208,617,018...208,686,240
Ensembl chr 1:208,639,115...208,685,805

G

syntaxin 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of STX7 mRNA

NCBI chr 1:21,197,075...21,237,320
Ensembl chr 1:21,197,075...21,237,279

G

sulfatase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SULF2 mRNA

NCBI chr 3:154,822,079...154,904,566
Ensembl chr 3:154,822,085...154,904,415

G

SPT16 homolog, facilitates chromatin remodeling subunit

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SUPT16H mRNA

NCBI chr15:24,867,697...24,904,818
Ensembl chr15:24,866,489...24,904,846

G

SUV39H2 histone lysine methyltransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SUV39H2 mRNA

NCBI chr17:74,756,290...74,775,332
Ensembl chr17:74,756,306...74,775,332

G

switching B-cell complex subunit SWAP70

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SWAP70 mRNA

NCBI chr 1:164,267,588...164,328,796
Ensembl chr 1:164,267,609...164,328,794

G

synaptonemal complex central element protein 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYCE2 mRNA

NCBI chr19:23,266,236...23,291,265
Ensembl chr19:23,268,869...23,300,980

G

synapse defective Rho GTPase homolog 2

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYDE2 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of SYDE2 mRNA

NCBI chr 2:234,897,975...234,930,994
Ensembl chr 2:234,897,717...234,930,994

G

synaptogyrin 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYNGR3 mRNA

NCBI chr10:13,710,553...13,715,309
Ensembl chr10:13,704,998...13,715,669

G

synaptotagmin-like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of SYTL2 mRNA

NCBI chr 1:144,272,870...144,379,310
Ensembl chr 1:144,273,360...144,379,222

G

synaptotagmin-like 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYTL4 mRNA

NCBI chr X:97,135,496...97,185,867
Ensembl chr X:97,135,500...97,185,854

G

synaptotagmin-like 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of SYTL5 mRNA

NCBI chr X:12,775,529...13,030,134
Ensembl chr X:12,788,698...13,030,175

G

transforming, acidic coiled-coil containing protein 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TACC3 mRNA

NCBI chr14:77,051,209...77,065,343
Ensembl chr14:77,051,215...77,065,219

G

tumor-associated calcium signal transducer 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TACSTD2 mRNA

NCBI chr 4:96,707,950...96,709,650
Ensembl chr 4:96,707,951...96,709,650

G

TATA-box binding protein associated factor 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TAF5 mRNA

NCBI chr 1:245,958,428...245,973,914
Ensembl chr 1:245,958,428...245,973,914

G

tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TANC2 mRNA

NCBI chr10:90,553,124...90,873,477
Ensembl chr10:90,553,002...90,868,756

G

TAO kinase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TAOK3 mRNA

NCBI chr12:39,312,354...39,473,656
Ensembl chr12:39,314,027...39,461,244

G

threonyl-tRNA synthetase 2, mitochondrial

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TARS2 mRNA

NCBI chr 2:183,293,095...183,310,210
Ensembl chr 2:183,293,097...183,310,184

G

tubulin folding cofactor D

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TBCD mRNA

NCBI chr10:106,717,340...106,874,126
Ensembl chr10:106,717,367...106,874,122

G

transducin (beta)-like 1 X-linked

decreases expression

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of TBL1X mRNA

NCBI chr X:41,574,558...41,731,117
Ensembl chr X:41,576,047...41,731,101

G

transcription factor 19

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TCF19 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of TCF19 mRNA

NCBI chr20:3,218,756...3,222,861
Ensembl chr20:3,218,693...3,223,271

G

transcription factor 7 like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TCF7L1 mRNA

NCBI chr 4:104,680,734...104,846,086
Ensembl chr 4:104,680,739...104,845,287

G

tyrosyl-DNA phosphodiesterase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TDP1 mRNA

NCBI chr 6:119,163,192...119,231,029
Ensembl chr 6:119,163,166...119,231,021

G

trans-2,3-enoyl-CoA reductase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TECR mRNA

NCBI chr19:24,526,700...24,568,168
Ensembl chr19:24,541,615...24,568,168

G

testis expressed 30

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TEX30 mRNA

NCBI chr 9:46,243,416...46,252,273
Ensembl chr 9:46,242,748...46,252,249

G

transcription factor AP-2 gamma

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TFAP2C mRNA

NCBI chr 3:161,315,114...161,322,998
Ensembl chr 3:161,315,031...161,322,995

G

transcription factor Dp-1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFDP1 mRNA

NCBI chr16:76,162,040...76,200,871
Ensembl chr16:76,162,043...76,200,817

G

trefoil factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFF1 mRNA

NCBI chr20:9,235,736...9,239,597
Ensembl chr20:9,235,736...9,239,597

G

trefoil factor 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TFF3 mRNA

NCBI chr20:9,193,259...9,197,969
Ensembl chr20:9,193,262...9,198,054

G

tissue factor pathway inhibitor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TFPI mRNA

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

transforming growth factor, beta 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFB2 mRNA

NCBI chr13:98,160,075...98,261,771
Ensembl chr13:98,160,087...98,261,405

G

transforming growth factor, beta receptor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGFBR1 mRNA

NCBI chr 5:61,653,773...61,710,777
Ensembl chr 5:61,653,233...61,710,777

G

TGFB-induced factor homeobox 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TGIF1 mRNA

NCBI chr 9:110,748,094...110,757,714
Ensembl chr 9:110,720,921...110,757,802

G

TGFB-induced factor homeobox 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TGIF2 mRNA

NCBI chr 3:145,333,152...145,348,599
Ensembl chr 3:145,333,418...145,348,596

G

thrombospondin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THBS1 mRNA

NCBI chr 3:105,056,293...105,071,445
Ensembl chr 3:105,056,292...105,071,440

G

thioesterase superfamily member 6

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THEM6 mRNA

NCBI chr 7:106,606,570...106,609,747
Ensembl chr 7:106,606,570...106,609,746

G

thrombospondin type 1 domain containing 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of THSD4 mRNA

NCBI chr 8:60,384,636...60,984,419
Ensembl chr 8:60,386,875...61,024,995

G

TOPBP1-interacting checkpoint and replication regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TICRR mRNA

NCBI chr 1:133,597,618...133,639,513
Ensembl chr 1:133,597,716...133,639,523

G

TP53 induced glycolysis regulatory phosphatase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TIGAR mRNA

NCBI chr 4:159,927,136...159,946,077
Ensembl chr 4:159,927,139...159,946,029

G

timeless circadian regulator

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TIMELESS mRNA

NCBI chr 7:654,804...678,769
Ensembl chr 7:654,822...678,738

G

TIMP metallopeptidase inhibitor 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TIMP2 mRNA

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

G

timeless interacting protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TIPIN mRNA

NCBI chr 8:64,780,813...64,801,358
Ensembl chr 8:64,780,828...64,801,352

G

thymidine kinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TK1 mRNA

NCBI chr10:103,034,755...103,046,125
Ensembl chr10:103,031,521...103,046,920

G

triokinase and FMN cyclase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TKFC mRNA

NCBI chr 1:207,238,230...207,253,035
Ensembl chr 1:207,236,557...207,252,737

G

TLE family member 1, transcriptional corepressor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TLE1 mRNA

NCBI chr 5:85,851,827...85,934,806
Ensembl chr 5:85,851,827...85,934,774

G

transmembrane 4 L six family member 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TM4SF1 mRNA

NCBI chr 2:141,456,950...141,466,146
Ensembl chr 2:141,453,310...141,466,146

G

transmembrane and coiled-coil domain family 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMCC1 mRNA

NCBI chr 4:149,069,252...149,239,585
Ensembl chr 4:149,069,260...149,239,620

G

transmembrane p24 trafficking protein family member 8

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMED8 mRNA

NCBI chr 6:106,806,973...106,841,271
Ensembl chr 6:106,810,420...106,843,216

G

transmembrane protein 106C

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM106C mRNA

NCBI chr 7:129,088,468...129,094,128
Ensembl chr 7:129,088,498...129,094,130

G

transmembrane protein 164

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM164 mRNA

NCBI chr X:106,288,019...106,448,642
Ensembl chr X:106,289,371...106,448,640

G

transmembrane protein 237

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM237 mRNA

NCBI chr 9:60,533,348...60,569,253
Ensembl chr 9:60,535,233...60,572,567

G

transmembrane protein 38B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM38B mRNA

NCBI chr 5:68,460,304...68,496,026
Ensembl chr 5:68,460,304...68,496,025

G

transmembrane protein 45b

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMEM45B mRNA

NCBI chr 8:29,865,276...29,910,453
Ensembl chr 8:29,865,278...29,910,453

G

transmembrane protein 64

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM64 mRNA

NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:28,698,918...28,745,330

G

transmembrane protein 65

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMEM65 mRNA

NCBI chr 7:90,336,997...90,378,930
Ensembl chr 7:90,274,142...90,379,474

G

transmembrane protein 97

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMEM97 mRNA

NCBI chr10:63,438,228...63,447,311
Ensembl chr10:63,438,222...63,589,730

G

thymopoietin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMPO mRNA

NCBI chr 7:25,642,752...25,667,756
Ensembl chr 7:25,586,725...25,667,727

G

transmembrane serine protease 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMPRSS3 mRNA

NCBI chr20:9,254,102...9,273,808
Ensembl chr20:9,254,109...9,274,363

G

thymosin beta 15B2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMSB15A mRNA

NCBI chr X:100,298,705...100,300,820
Ensembl chr X:100,298,514...100,300,886

G

thiol methyltransferase 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TMT1A mRNA

NCBI chr 7:131,452,099...131,460,154
Ensembl chr 7:131,451,641...131,460,154

G

transmembrane O-mannosyltransferase targeting cadherins 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TMTC2 mRNA

NCBI chr 7:40,392,377...40,806,685
Ensembl chr 7:40,394,220...40,807,298

G

tumor necrosis factor

decreases secretion

2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased secretion of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

TNF alpha induced protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFAIP1 mRNA

NCBI chr10:63,417,774...63,432,466
Ensembl chr10:63,417,775...63,432,466

G

TNF receptor superfamily member 12A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFRSF12A mRNA

NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045

G

TNF receptor superfamily member 21

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TNFRSF21 mRNA

NCBI chr 9:17,879,156...17,954,085
Ensembl chr 9:17,879,156...17,954,085

G

DNA topoisomerase II alpha

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TOP2A mRNA

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

DNA topoisomerase II binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TOPBP1 mRNA

NCBI chr 8:103,887,805...103,931,662
Ensembl chr 8:103,887,865...103,931,674

G

tumor protein p53 inducible nuclear protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TP53INP1 mRNA

NCBI chr 5:24,253,986...24,272,250
Ensembl chr 5:24,260,568...24,267,968

G

tumor protein D52

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TPD52 mRNA

NCBI chr 2:92,735,365...92,816,079
Ensembl chr 2:92,735,620...92,816,622

G

TPD52 like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPD52L1 mRNA

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:26,172,170...26,291,109

G

triosephosphate isomerase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPI1 mRNA

NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541

G

tropomyosin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TPM1 mRNA

NCBI chr 8:67,635,479...67,662,330
Ensembl chr 8:67,635,479...67,662,802

G

TPX2, microtubule nucleation factor

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TPX2 mRNA

NCBI chr 3:141,318,428...141,360,684
Ensembl chr 3:141,318,455...141,360,468

G

transcriptional regulating factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TRERF1 mRNA

NCBI chr 9:13,631,619...13,858,326
Ensembl chr 9:13,634,126...13,857,029

G

tribbles pseudokinase 1

multiple interactions
decreases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TRIB1 mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in decreased expression of TRIB1 mRNA

NCBI chr 7:91,206,579...91,213,126
Ensembl chr 7:91,206,579...91,214,731

G

tripartite motif-containing 59

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TRIM59 mRNA

NCBI chr 2:153,269,210...153,281,185
Ensembl chr 2:153,268,584...153,281,031

G

thyroid hormone receptor interactor 13

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TRIP13 mRNA

NCBI chr 1:29,357,093...29,402,078
Ensembl chr 1:29,357,130...29,402,074

G

TSC22 domain family, member 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSC22D3 mRNA

NCBI chr X:104,217,898...104,277,886
Ensembl chr X:104,217,925...104,276,861

G

translin

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TSN mRNA

NCBI chr13:29,366,405...29,377,251
Ensembl chr13:29,364,110...29,377,599

G

tetraspanin 31

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSPAN31 mRNA

NCBI chr 7:62,889,552...62,892,428
Ensembl chr 7:62,889,552...62,898,388

G

TSPY-like 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TSPYL1 mRNA

NCBI chr20:38,082,003...38,084,562
Ensembl chr20:38,081,951...38,084,554
Ensembl chr20:38,081,951...38,084,554

G

tetratricopeptide repeat domain 39B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TTC39B mRNA

NCBI chr 5:97,603,329...97,708,103
Ensembl chr 5:97,609,392...97,736,270

G

Ttk protein kinase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TTK mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of TTK mRNA

NCBI chr 8:84,754,329...84,792,653
Ensembl chr 8:84,754,315...84,792,651

G

tubulin, beta 2A class IIa

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TUBB2A mRNA

NCBI chr17:30,796,842...30,800,713
Ensembl chr17:30,747,503...30,800,714

G

tubulin, beta 4B class IVb

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBB4B mRNA

NCBI chr 3:8,037,838...8,040,294
Ensembl chr 3:8,037,799...8,040,296

G

tubulin, beta 5 class I

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBB mRNA

NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940

G

tubulin, delta 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBD1 mRNA

NCBI chr10:71,367,936...71,391,387
Ensembl chr10:71,368,133...71,391,266

G

tubulin, gamma 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBG1 mRNA

NCBI chr10:86,052,845...86,059,436
Ensembl chr10:86,052,743...86,059,433

G

tubulin gamma complex component 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TUBGCP4 mRNA

NCBI chr 3:108,141,081...108,172,207
Ensembl chr 3:108,141,625...108,169,437

G

tuftelin 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TUFT1 mRNA

NCBI chr 2:182,259,457...182,306,296
Ensembl chr 2:182,260,398...182,306,192

G

TUB like protein 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TULP4 mRNA

NCBI chr 1:46,682,416...46,813,167
Ensembl chr 1:46,682,863...46,809,688

G

twist family bHLH transcription factor 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of TWIST1 mRNA

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:50,674,678...50,677,653

G

thymidylate synthetase

multiple interactions
increases expression

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of TYMS mRNA
2,3-bis(3'-hydroxybenzyl)butyrolactone results in increased expression of TYMS mRNA

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

G

ubiquitin-conjugating enzyme E2B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2B mRNA

NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665

G

ubiquitin-conjugating enzyme E2H

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2H mRNA

NCBI chr 4:58,834,674...58,930,156
Ensembl chr 4:58,834,674...58,930,156

G

ubiquitin-conjugating enzyme E2, J1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2J1 mRNA

NCBI chr 5:47,422,476...47,441,476
Ensembl chr 5:47,422,587...47,441,461

G

ubiquitin conjugating enzyme E2 QL1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2QL1 mRNA

NCBI chr 1:33,548,814...33,589,174
Ensembl chr 1:33,548,814...33,589,174

G

ubiquitin-conjugating enzyme E2T

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UBE2T mRNA

NCBI chr13:46,403,352...46,413,854
Ensembl chr13:46,403,375...46,414,835

G

ubiquitin-conjugating enzyme E2W

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UBE2W mRNA

NCBI chr 5:2,690,742...2,754,491
Ensembl chr 5:2,690,763...2,814,965

G

ubiquitin protein ligase E3 component n-recognin 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UBR7 mRNA

NCBI chr 6:121,898,613...121,918,480
Ensembl chr 6:121,898,623...121,918,477

G

ubiquitin C-terminal hydrolase L5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UCHL5 mRNA

NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502

G

uridine-cytidine kinase 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UCK2 mRNA

NCBI chr13:79,380,807...79,438,121
Ensembl chr13:79,383,846...79,438,352

G

ubiquitin-like with PHD and ring finger domains 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UHRF1 mRNA

NCBI chr 9:1,133,117...1,154,639
Ensembl chr 9:1,134,909...1,154,631

G

uracil-DNA glycosylase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UNG mRNA

NCBI chr12:42,485,276...42,494,217
Ensembl chr12:42,485,276...42,494,206

G

UPF3B, regulator of nonsense mediated mRNA decay

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of UPF3B mRNA

NCBI chr X:116,335,308...116,353,332
Ensembl chr X:116,335,308...116,353,236

G

ubiquitin specific peptidase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of USP1 mRNA

NCBI chr 5:113,587,564...113,598,934
Ensembl chr 5:113,587,564...113,598,932

G

ubiquitin specific peptidase 3

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of USP3 mRNA

NCBI chr 8:67,078,249...67,154,109
Ensembl chr 8:67,079,927...67,154,111

G

uronyl-2-sulfotransferase

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of UST mRNA

NCBI chr 1:2,666,983...2,962,276
Ensembl chr 1:2,669,592...2,962,044

G

valyl-tRNA synthetase 2, mitochondrial

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VARS2 mRNA

NCBI chr20:3,077,132...3,087,994
Ensembl chr20:3,077,132...3,087,994

G

vascular endothelial growth factor A

multiple interactions

2,3-bis(3'-hydroxybenzyl)butyrolactone inhibits the reaction [Estradiol results in increased secretion of VEGFA protein]; [Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of VEGFA mRNA

PMID:17289903 PMID:19167446

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vitamin K epoxide reductase complex, subunit 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VKORC1 mRNA

NCBI chr 1:182,502,491...182,505,012
Ensembl chr 1:182,500,844...182,505,008

G

VRK serine/threonine kinase 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of VRK1 mRNA

NCBI chr 6:124,914,770...124,981,508
Ensembl chr 6:124,914,855...124,981,436

G

WD repeat and HMG-box DNA binding protein 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDHD1 mRNA

NCBI chr15:20,478,310...20,523,106
Ensembl chr15:20,489,291...20,523,096

G

WD repeat domain 54

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDR54 mRNA

NCBI chr 4:115,654,968...115,677,979
Ensembl chr 4:115,654,968...115,661,562

G

WD repeat domain 76

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WDR76 mRNA

NCBI chr 3:108,456,784...108,491,528
Ensembl chr 3:108,456,815...108,490,840

G

WD repeat domain, phosphoinositide interacting 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of WIPI1 mRNA

NCBI chr10:94,542,946...94,580,174
Ensembl chr10:94,542,946...94,579,846

G

WIZ zinc finger

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of WIZ mRNA

NCBI chr 7:11,366,837...11,395,279
Ensembl chr 7:11,367,035...11,395,490

G

yippee-like 2

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of YPEL2 mRNA

NCBI chr10:71,746,308...71,803,843
Ensembl chr10:71,746,311...71,803,911

G

yippee-like 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of YPEL5 mRNA

NCBI chr 6:22,656,284...22,671,741
Ensembl chr 6:22,656,285...22,671,691

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, epsilon

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of YWHAE mRNA

NCBI chr10:60,584,665...60,622,352
Ensembl chr10:60,584,652...60,671,589

G

zinc finger and BTB domain containing 26

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZBTB26 mRNA

NCBI chr 3:21,195,319...21,207,925
Ensembl chr 3:21,195,319...21,207,942

G

zinc finger and BTB domain containing 4

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZBTB4 mRNA

NCBI chr10:54,480,698...54,501,492
Ensembl chr10:54,485,071...54,501,492

G

zinc finger, C2HC-type containing 1A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZC2HC1A mRNA

NCBI chr 2:94,287,352...94,324,655
Ensembl chr 2:94,287,354...94,324,882

G

zinc finger CCCH type containing 12A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZC3H12A mRNA

NCBI chr 5:137,376,562...137,385,351
Ensembl chr 5:137,376,564...137,385,351

G

zinc finger DHHC-type palmitoyltransferase 7

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZDHHC7 mRNA

NCBI chr19:48,139,309...48,156,673
Ensembl chr19:48,139,527...48,156,673

G

zinc finger AN1-type containing 2A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZFAND2A mRNA

NCBI chr12:15,161,601...15,172,679
Ensembl chr12:15,161,639...15,172,677

G

zinc finger protein 277

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF277 mRNA

NCBI chr 6:57,383,454...57,512,785
Ensembl chr 6:57,383,951...57,512,765

G

zinc finger protein 292

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF292 mRNA

NCBI chr 5:49,384,177...49,468,177
Ensembl chr 5:49,387,893...49,468,265

G

zinc finger protein 354A

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF354A mRNA

NCBI chr10:35,396,242...35,408,069
Ensembl chr10:35,396,231...35,408,068

G

zinc finger protein 367

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZNF367 mRNA

NCBI chr17:965,161...984,290
Ensembl chr17:965,161...984,287

G

zinc finger protein 467

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF467 mRNA

NCBI chr 4:77,385,752...77,394,709
Ensembl chr 4:77,385,758...77,392,229

G

zinc finger protein 641

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZNF641 mRNA

NCBI chr 7:129,434,576...129,444,847
Ensembl chr 7:129,434,576...129,444,644

G

zinc finger protein 703

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZNF703 mRNA

NCBI chr16:65,076,507...65,080,677
Ensembl chr16:65,076,507...65,080,677

G

zinc finger FYVE-type containing 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZFYVE1 mRNA

NCBI chr 6:103,184,938...103,234,111
Ensembl chr 6:103,184,938...103,234,039

G

zinc finger with KRAB and SCAN domains 1

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZKSCAN1 mRNA

NCBI chr12:16,966,287...16,987,680
Ensembl chr12:16,966,654...16,983,865

G

zinc finger MYM-type containing 5

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZMYM5 mRNA

NCBI chr15:30,920,479...30,941,249
Ensembl chr15:30,923,241...30,941,240

G

zwilch kinetochore protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZWILCH mRNA

NCBI chr 8:64,638,401...64,670,911
Ensembl chr 8:64,637,672...64,675,916

G

ZW10 interacting kinetochore protein

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in increased expression of ZWINT mRNA

NCBI chr20:15,938,157...15,953,997
Ensembl chr20:15,938,157...15,953,957

G

zinc finger, X-linked, duplicated B

multiple interactions

[Coumestrol co-treated with 2,3-bis(3'-hydroxybenzyl)butyrolactone] results in decreased expression of ZXDB mRNA

NCBI chr  X:59,700,765...59,706,737
Ensembl chr  X:59,701,178...59,703,871
Ensembl chr  X:59,701,178...59,703,871

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	19844
chemical entity	19842
group	19800
polyatomic entity	19799
molecule	19702
cyclic compound	19516
organic cyclic compound	19498
organic aromatic compound	19366
phenylpropanoid	11297
lignan	1705
Enterolactone	965
Path 2
Term	Annotations
CHEBI ontology	19844
subatomic particle	19842
composite particle	19842
hadron	19842
baryon	19842
nucleon	19809
atomic nucleus	19842
atom	19842
main group element atom	19792
p-block element atom	19792
p-block molecular entity	19792
carbon group molecular entity	19738
organic molecular entity	19734
organic molecule	19687
organic cyclic compound	19498
organic aromatic compound	19366
phenylpropanoid	11297
lignan	1705
Enterolactone	965

paths to the root